Thomas Jefferson University

Jefferson Digital Commons
Department of Cancer Biology Faculty Papers

Department of Cancer Biology

9-1-2018

miR-196b target screen reveals mechanisms maintaining
leukemia stemness with therapeutic potential.
Sara E. Meyer
Thomas Jefferson University; Cincinnati Children’s Hospital Medical Center

David E. Muench
Cincinnati Children’s Hospital Medical Center

Andrew M. Rogers
Cincinnati Children’s Hospital Medical Center

Tess J. Newkold
Cincinnati Children’s Hospital Medical Center
Follow this and additional works at: https://jdc.jefferson.edu/cbfp

Emily Orr

Part of Children’s
the Medical
Cell Biology
Commons,
Cincinnati
Hospital
Medical
Center and the Oncology Commons

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Meyer, Sara E.; Muench, David E.; Rogers, Andrew M.; Newkold, Tess J.; Orr, Emily; O'Brien, Eric;
Perentesis, John P.; Doench, John G.; Lal, Ashish; Morris, Patrick J.; Thomas, Craig J.;
Lieberman, Judy; McGlinn, Edwina; Aronow, Bruce J.; Salomonis, Nathan; and Grimes, H.
Leighton, "miR-196b target screen reveals mechanisms maintaining leukemia stemness with
therapeutic potential." (2018). Department of Cancer Biology Faculty Papers. Paper 139.
https://jdc.jefferson.edu/cbfp/139
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Cancer Biology Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Sara E. Meyer, David E. Muench, Andrew M. Rogers, Tess J. Newkold, Emily Orr, Eric O'Brien, John P.
Perentesis, John G. Doench, Ashish Lal, Patrick J. Morris, Craig J. Thomas, Judy Lieberman, Edwina
McGlinn, Bruce J. Aronow, Nathan Salomonis, and H. Leighton Grimes

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/cbfp/139

Published Online: 11 July, 2018 | Supp Info: http://doi.org/10.1084/jem.20171312
Downloaded from jem.rupress.org on October 31, 2018

ARTICLE

miR-196b target screen reveals mechanisms
maintaining leukemia stemness with therapeutic
potential
Sara E. Meyer1, David E. Muench1, Andrew M. Rogers1, Tess J. Newkold1, Emily Orr1, Eric O’Brien2, John P. Perentesis2, John G. Doench3,
Ashish Lal4, Patrick J. Morris5, Craig J. Thomas5, Judy Lieberman6,7, Edwina McGlinn8, Bruce J. Aronow9, Nathan Salomonis9, and
H. Leighton Grimes1,10

We have shown that antagomiR inhibition of miRNA miR-21 and miR-196b activity is sufficient to ablate MLL-AF9 leukemia
stem cells (LSC) in vivo. Here, we used an shRNA screening approach to mimic miRNA activity on experimentally verified
miR-196b targets to identify functionally important and therapeutically relevant pathways downstream of oncogenic miRNA
in MLL-r AML. We found Cdkn1b (p27Kip1) is a direct miR-196b target whose repression enhanced an embryonic stem cell–like
signature associated with decreased leukemia latency and increased numbers of leukemia stem cells in vivo. Conversely,
elevation of p27Kip1 significantly reduced MLL-r leukemia self-renewal, promoted monocytic differentiation of leukemic
blasts, and induced cell death. Antagonism of miR-196b activity or pharmacologic inhibition of the Cks1-Skp2–containing
SCF E3-ubiquitin ligase complex increased p27Kip1 and inhibited human AML growth. This work illustrates that understanding
oncogenic miRNA target pathways can identify actionable targets in leukemia.

Introduction

11q23 rearrangements account for ∼10% of chromosomal abnormalities in leukemia and result in fusion of the Mixed-Lineage
Leukemia (MLL) gene with a multitude of partners (such as AF9).
11q23/MLL rearrangements (MLL-r) are associated with a poor
prognosis in acute myeloid leukemia (AML). The overall survival
is only 20–40% with current treatment, perhaps due to the high
frequency of leukemia stem cells (LSCs; Huret et al., 2001; Cox
et al., 2004; Somervaille and Cleary, 2006; Döhner et al., 2010;
Grimwade et al., 2010). Thus, the identification of therapeutically targetable pathways maintaining LSC self-renewal or survival is a high priority.
Expression of MLL fusion proteins, such as MLL-AF9, is sufficient to transform normal bone marrow hematopoietic stem/progenitor cells (Corral et al., 1996; Krivtsov et al., 2006; Somervaille
and Cleary, 2006; Chen et al., 2008b). Thus, new approaches for
treating MLL-r leukemia use small molecules that specifically

block the interaction of MLL fusion proteins with transcriptional
complexes containing Menin (Grembecka et al., 2012), DOT1L
(Daigle et al., 2011), and BET family proteins (Dawson et al.,
2011) or inhibit key MLL target genes, such as CDK6 (Placke et al.,
2014), which are known to be important for the transformation
and maintenance of this leukemia subgroup. Although clinical
trials are still underway for these newer classes of inhibitors in
a variety of different cancers, reports of resistance mechanisms
are beginning to emerge (Fong et al., 2015; O’Leary et al., 2016),
suggesting that novel strategies that synergize with these agents
to enhance their efficacy or restore drug sensitivity are needed.
MLL-fusion proteins direct expression of the HOXA cluster
(HOXA9 and HOXA7) and MEIS1 oncogenes, but the role of specific HOX genes in transformation varies with the MLL-fusion
partner (Armstrong et al., 2002; Ayton and Cleary, 2003; Kumar
et al., 2004; So et al., 2004; Erfurth et al., 2008), suggesting
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that other factors may play a role in the oncogenesis of MLL/
HOX signaling. The evolutionarily conserved miR-196 family
MIR196B, MIR196A1, and MIR196A2 encoded within the HOX
gene clusters are overexpressed in AML and share identical seed
sequences. In particular, MLL-r leukemias overexpress miR196b (Jongen-Lavrencic et al., 2008; Li et al., 2008; Marcucci et
al., 2008; Schotte et al., 2010), and elevated miR-196b expression in AML is associated with reduced survival (Li et al., 2012),
suggesting that miR-196b might play an important role in AML.
In agreement with these observations, we previously showed
that simultaneous inhibition of miR-21 and miR-196b reduced
MLL-AF9 LSC and protected mice from established leukemia
(Velu et al., 2014).
While miRNA target prediction algorithms can provide guidance about potential miRNA-regulated genes, they do not account
for cellular context or functional relevance, and they penalize
binding scores for noncanonical miRNA recognition elements.
Hence, alternate approaches are needed that can identify functionally important direct miRNA–mRNA target interactions
in specific cellular contexts, such as leukemia. We used a twostep unbiased experimental workflow combining a biotinylated
miRNA mimic pulldown approach with pooled in vivo shRNA
screening to identify miR-196b targets with important functional
consequences in MLL-r leukemia. We identify Cdkn1b/p27Kip1 as
a target of miR-196b, whose repression significantly accelerates
MLL-AF9 leukemia. Follow-up analyses of signaling pathways revealed that when p27Kip1 expression was repressed in MLL-AF9
AML cells, an embryonic stem cell (ESC)–like self-renewal/proliferation program was activated, while myeloid differentiation
programming was reduced. Conversely, either specific blockade
of the miR-196b interaction with Cdkn1b mRNA or small molecule inhibition of SCFSKP2 E3-ubiquitin ligase complex increased
p27Kip1 protein levels, promoted monocytic differentiation, significantly reduced leukemogenic potential, and increased cell
death of AML cells. Finally, SCFSKP2 inhibition acted synergistically with Menin/MLL (Ml-1), CDK4/6 (Palbociclib), and BET
(I-BET151) inhibitors to block the growth of human MLL-r–containing AML cells. Thus, our work provides global mechanistic
insight into the function of an oncogenic miRNA and illustrates
the utility of exploiting miRNA signaling to identify actionable
targets in leukemia.

Results

Unbiased global identification of miR-196b functions
in human 11q23 AM
The miR-196b–directed signaling pathway in cancer, including
11q23 AML, is largely unknown. To globally define the miR-196b
direct targets in AML, we adapted a biochemical approach to
identify the mRNA transcripts bound by miR-196b–containing-RISC complexes in human AML cells harboring t(9;11),
MLL-AF9 translocation (THP1 cells; Odero et al., 2000; Nonne
et al., 2010; Lal et al., 2011). Using a miRNA target pulldown
approach, transfection of biotinylated miRNA mimics (Bi-miR)
permits purification of Bi-miR-196b target–containing RISC
complexes using the biotin tag (Fig. 1 A). Identities of Bi-miR–
associated transcripts were then revealed by microarray analyMeyer et al.
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ses, and validated by quantitative RT-PCR (RT-qPCR). We used
two different human cell lines for pulldown studies: THP1 AML
cells and HEK293 cells. Human embryonic kidney (HEK) cells
express HOXA genes and miR-196b, permitting a comparative
analysis of two miR-196b–relevant cellular contexts, one of
which is leukemic. In both HEK293 and THP1 cells, Bi-miR-196b
bound to previously known target HOXA7, which was enriched
∼500-fold compared with negative control Caenorhabditis elegans Bi-cel-67 pulldown (Fig. 1 C and Fig. S1 A; Yekta et al., 2004;
Wong et al., 2015). Bi-miR-196b also repressed target protein
expression (Fig. S1 B). Furthermore, microarray analyses identified 262 miR-196b target candidates with twofold or greater
enrichment in Bi-miR-196b pulldown fractions compared with
Bi-cel-67 control pulldowns in two or more independent experiments using THP1 AML cells (Fig. 1 B and Table S1). Analyses
of each THP1 AML cell pulldown experiment independently
identified an additional 1,708 candidate targets enriched at least
twofold in THP1 cells (Table S1). These targets were reproducibly enriched greater than twofold in independent Bi-miR-196b
pulldown experiments in THP1 AML cells, as well as HEK293
cells (Fig. 1 C and Fig. S1 A). Thus, the biotinylated miRNA pulldown approach reproducibly captures putative miR-196b targets from AML cells and also demonstrates context specificity
for some miRNA target interactions.
To validate that the Bi-miR-196b pulldown assays identify
novel targets, we first intersected pulldown targets with those
predicated by computational algorithms PITA (Kertesz et al.,
2007), miRanda (Enright et al., 2003; John et al., 2004; Betel et
al., 2008), TargetScan7.0 (Lewis et al., 2003, 2005; Agarwal et
al., 2015), and DIANA (Maragkakis et al., 2009a,b; Papadopoulos
et al., 2009). Of the 162 pulldown targets mapped to known gene
IDs from Fig. 1 B, 90 were not predicted by algorithms, suggesting that an experimental approach can identify novel miRNA
targets (Fig. S1 C and Table S1). Next, to provide independent
validation for miRNA binding to genes in our pulldown datasets, we manually located miR-196b binding sites with a minimum of six consecutive nucleotide-seed matches beginning at
either α, β, or γ positions (Ellwanger et al., 2011). These sites
were queried for binding by Argonaute (AGO) proteins using
published high-throughput sequencing of RNA isolated by
cross-linking immunoprecipitation (HITS-CLIP) datasets (Yang
et al., 2015). CDKN1B is shown as a representative in Fig. S1 D.
Of the 17 pulldown targets examined, 100% overlapped with at
least one AGO-CLIP peak and 15/17 showed multiple AGO-CLIP
datasets overlapping each miR binding site (Fig. S1 E). Using
luciferase reporter assays, we validated 12/13 target sites located in 10 different pulldown target genes for miR-196b binding and luciferase repression (Fig. 1 D). Finally, we analyzed
existing RNA-sequencing (RNA-seq) data from E9.5 embryos
with limiting alleles of miR-196 (196a2+/−;b−/−, 196a2−/−;b+/−, or
196a2−/−;b−/− versus 196a2+/−;b+/+; Wong et al., 2015). Analysis of
the RNA-seq data revealed increased expression of Bi-miR-196b
pulldown targets in a miR-196 allele dose–dependent manner
(Fig. S1 F and Table S1). In sum, these data demonstrate reproducibility of biotinylated miRNA target pulldowns, and confirm
the direct binding of miR-196b and/or AGO complexes to pulldown target mRNAs.
Journal of Experimental Medicine
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Figure 1. Unbiased identification of direct miR-196b targets in human 11q23 AML. (A) Schematic of biotinylated miRNA-mimic (Bi-miR) pulldown
approach. (B) Heat map of putative miR-196b target gene pulldowns enrichments from three independent pulldowns in 11q23 mutant THP1 AML cells. Displayed genes were enriched at least twofold in Bi-miR-196b pulldowns relative to matched Bi-cel-67 pulldowns in two of three experiments. The corresponding
fold change Bi-miR-196b versus Bi-cel-67 inputs are shown for each gene. (C) Independent RT-qPCR validation of miR target mRNA pulldown. The average fold
pulldown (± SEM) relative to matched input controls for each Bi-cel-67 control (black bars) and Bi-miR-196b mimic (white bars) in at least three independent
experiments in THP1 cells. Statistical significance by paired t tests for each gene versus Bi-cel-67 control. (D) Functional miR target validation. Average fold
change ± SEM repression by miR-196b (miR-196b-5p) relative to negative control (NC) of indicated miR-196b binding sites in three independent Luciferase
reporter assay experiments. Multiple binding sites in the same gene are distinguished by “1” and “2”. Statistical significance was determined using a two-way
ANOVA versus NC. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. n.s., not significant.

An in vivo shRNA screen resolves oncogenic miR-196b
signaling in MLL-AF9 leukemogenesis
To determine targets with functional importance in leukemogenesis, we devised an in vivo shRNA screen. Previously, similar screens have been used to identify novel therapeutic targets
in MLL-AF9 leukemia or to phenocopy miRNA activity in vitro
Meyer et al.
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(Mavrakis et al., 2010; Zuber et al., 2011; Miller et al., 2013; Chen
et al., 2015). Given that miRNA repress target mRNA stability
and/or translation, we hypothesized that hairpins enriched in the
shRNA screen would mimic miR-196b oncogenic activity. First,
we performed an engraftment test on three mice transplanted
with MLL-AF9 cells transduced with a randomly barcoded lentiJournal of Experimental Medicine
https://doi.org/10.1084/jem.20171312
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viral library at constant multiplicity of infection (MOI) ∼0.2 to
produce one unique barcode per cell after selection with puromycin. DNA from resultant AML in moribund mice was sequenced
and compared with DNA from nontransplanted, transduced,
and selected MLL-AF9 cells as input control, quantifying an
engraftment efficiency of ∼4%. Based on these data, to ensure
sufficient representation of each experimental hairpin in vivo,
we estimated that shRNA should be divided into random pools of
∼100 hairpins per 1 million MLL-AF9 cells transplanted into 10
mice per pool. Thus, at a 4% engraftment rate, each hairpin was
represented by 400 cells per mouse.
Given these parameters, to ensure adequate power and feasibility of the in vivo screen we restricted the number of miR-196b
pulldown targets analyzed. Specifically, we selected 116 screen
candidates that were enriched in at least one THP1 pulldown
experiment, 60 of which were also identified in the HEK293
pulldown and 103 that were predicted targets by computational
algorithms (PITA [Kertesz et al., 2007], miRanda [Enright et al.,
2003; John et al., 2004; Betel et al., 2008], TargetScan7.0 [Lewis
et al., 2003, 2005; Agarwal et al., 2015], and DIANA [Maragkakis
et al., 2009a,b; Papadopoulos et al., 2009]; Table S1). Priority was
given to genes with previously validated miR-196b target sites
such as HoxA7 (Yekta et al., 2004), genes associated with oncogenic or tumor suppressive pathways such as Cdkn1b (Polyak
et al., 1994; Zhang et al., 2013), Braf (Rajagopalan et al., 2002),
Cdk12 (Blazek et al., 2011), Phc2 (Isono et al., 2005), and Mdm4
(Parant et al., 2001), and genes involved in stemness or differentiation pathways such as Anxa1 (Machado et al., 2016), Epha7
(Nguyen et al., 2017), Ikzf1 (Winandy et al., 1995; Wang et al.,
1996), and Pou2f1 (Wang et al., 2004). In vivo examination of 116
candidates involved 632 individual hairpins (4–6 hairpins/gene)
were divided into 8 pools (Fig. 2 A). Twelve hairpins against four
control genes were also included in each pool.
As illustrated in Fig. 2 A, pooled shRNA-containing lentiviruses were transduced into MLL-AF9 leukemic splenocytes at
a constant MOI of ∼0.2, selected with puromycin, and transplanted into sublethally irradiated mice (n = 10/pool). Of the 116
miR-196b target genes screened, 78 genes with at least two hairpins per gene showing reproducible effects in at least four mice
per pool were subsequently scored. 33 genes showed enrichment,
while 45 were depleted compared with control hairpins (Table
S1). To test that hairpins were not stochastically selected in vivo,
we randomly divided mice from each pool into two groups and
found a significant correlation of hairpin enrichment and/or depletion across replicate mice in the two groups (Fig. 2 B). These
data indicate a biological function of hairpin activity in vivo, and
also demonstrate that the shRNA screen was adequately powered
to resolve miRNA target function in vivo using shRNA.
To illustrate the biological processes impacted by the miR-196b
target hairpins in our screen, we performed GO-Elite enrichment
analyses of the 116 genes targeted by hairpins grouped by screen
input versus screen output categories (enriched and depleted;
Table S1). To illustrate these data, we created a miR-196b target
interactome based on these ontologies (Fig. 2 C). Corresponding
shRNA screen enrichment or depletion scores of genes involved
in these different functional networks are graphed in Fig. S2 (A
and B). We note examples in which both enriched and depleted
Meyer et al.
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hairpins target different genes involved in the same basic biological processes (e.g., gene expression; Fig. 2 C). To validate our
pooled screen results, we assayed the activity of two hairpins
per gene that were enriched in the MLL-AF9 screen against candidates from each biological process for in vivo effects of target
repression on (1) disease latency as measured by overall animal
survival (Fig. 2, D–G; and Fig. S2 C) and (2) knockdown of mRNA
expression (Fig. S2 D). Compared with MLL-AF9 control (nontargeting [NT] or eT shRNA) transplanted mice, two independent
enriched shRNA against Cdkn1b, Slc9a6, Phc2, and Taf5l (Fig. 2,
D–G, respectively) significantly accelerated MLL-AF9 leukemogenesis, while shRNA against a depleted gene Zcchc9 had no
effect on latency (Fig. S2 C). In contrast, independent validation studies using two independent shRNA that were enriched
against HoxA7, Sptssa, Map2k6, Mdm4, Anapc5, Tmem184c, and
Hnrnpm showed either incomplete (one out of two hairpins) or
no (zero out of two hairpins) effect on disease latency in vivo as
compared with MLL-AF9 control (data not shown). These data
indicate that cyclin-dependent kinase Cdkn1b (p27Kip1), sodium-hydroxide exchanger Slc9a6 (Nhe6), Polycomb Group member Polyhomeotic homologue Phc2, and PCAF-associated factor
Taf5l represent a select group of miR-196b targets with tumor
suppressive activity in AML. In sum, repression of a subset of
miR-196b targets in vivo is selectively enriched by cooperation
with MLL-AF9 to promote leukemogenesis.
miR-196b direct-target Cdkn1b controls ESC-like programming
to maintain MLL-AF9 leukemia
To gain deeper mechanistic insight into the contribution of the
miR-196b targets in AML, we performed transcriptional profiling
of Cdkn1b (p27Kip1) and Phc2 knockdown cells. Cdkn1b and Phc2
were robustly selected in Bi-miR-196b pulldown experiments,
both are associated with cell cycle/cell death processes, independent shRNA targeting Cdkn1b or Phc2 were selected in the shRNA
screen, and knockdown of both genes independently accelerated
MLL-AF9 leukemogenesis in vivo. We identified 113 genes significantly differentially expressed in Cdkn1b-knockdown MLL-AF9
AML compared with NT control (Fig. 3 A; n = 2 per group). Gene
set enrichment analyses (GSEA) were performed by exploring the
MSigDB database, as well as other published gene sets previously
enriched in MLL-AF9 leukemia (Table S2; Krivtsov et al., 2006;
Somervaille et al., 2009). As expected, genes up-regulated in Cdkn1b-knockdown MLL-AF9 leukemia positively correlated to cell
cycle (e.g., Cdk4 and Ccnd2). However, up-regulated genes also
strongly correlated to an ESC core gene set (e.g., Hadh, Lmnb1,
Msh2, and Prmt1; Fig. 3 B; Wong et al., 2008). This enrichment is
not simply associated with accelerated leukemia pathogenesis,
as Phc2 knockdown similarly accelerated leukemia, but showed
reduced expression of the same ESC core gene set (Fig. S3, A and
B; and Table S2). Instead, Phc2 knockdown leukemia showed
increased expression of an adult stem cell gene set (Fig. S3 B;
Wong et al., 2008), which was conversely down-regulated in
Cdkn1b-knockdown MLL-AF9 leukemia (Fig. S3 C). Thus, there
appear to be multiple miR-196b targets regulating distinct stem
cell transcriptional programs important for the pathogenesis of
MLL-AF9 leukemia. Importantly, genes down-regulated upon
Cdkn1b knockdown in MLL-AF9 AML correspond with a poor
Journal of Experimental Medicine
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Figure 2. An in vivo shRNA screen functionally dissects miR-196b networks in MLL-AF9 leukemogenesis. (A) Schematic overview. In vivo shRNA-positive
selection screen of miR-196b-pulldown targets in primary MLL-AF9 leukemia. Leukemic splenocytes were transduced with eight different lentiviral shRNA
pools against 116 miR-196b target genes and transplanted into recipient mice (n = 10 mice/pool). Sequencing of pretransplant pools (input) versus leukemic
splenocytes (from moribund mice) identified 33 enriched and 45 deleted genes of at least two hairpins/gene over input control. (B) Replicate assay correlation.
For each enriched and depleted hairpin, recipient mice were divided into two groups/pool (n = 4–5 mice/group/pool) and plotted. The relatedness between
these two groups of mice was evaluated by Pearson correlation demonstrating that in vivo selection of hairpin activity is not stochastic (r = 0.8567). Examples
of genes with enriched (Scl9a6, Phc2, Sptssa, Taf5l, and Cdkn1b) or depleted (Zcchc9) shRNA are color coded. (C) Network analysis of screen targets by gene
ontology biological processes. RNAi screen enriched gene nodes (red), depleted gene nodes (blue), and unchanged gene nodes (white). Protein–protein interactions are denoted by black edges and putative miR-196b target transcript interactions experimentally identified in miR target pulldown assays are denoted
by gray edges. (D–G) In vivo validation of positive selection of individual targets. Kaplan-Meier survival curves of mice transplanted with MLL-AF9 leukemia
expressing individual shRNA hairpins against the indicated genes (n = 4 mice/group; 2 hairpins/gene). Non-targeting (NT) or EV (eT) were used as controls. miR196b pulldown targets Cdkn1b (D), Slc9a6 (E), Phc2 (F), and Taf5l (G) accelerated leukemia lethality. Significant p-values are reported by Log-rank (Mantel-Cox)
test for each hairpin compared with control. *, P ≤ 0.05; **, P ≤ 0.01; ****, P < 0.0001.
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prognosis gene signature in AML (Table S2; Yagi et al., 2003).
Given the high frequency of MLL-r leukemia stem cells, which
correlates with prognosis (Huret et al., 2001; Cox et al., 2004;
Somervaille and Cleary, 2006; Döhner et al., 2010; Grimwade et
al., 2010), and the stem cell signature activated by Cdkn1b knockdown, we focused subsequent studies on understanding the role
and therapeutic potential of p27Kip1 in AML.
Based on enrichment for the ESC core gene set (Wong et al.,
2008), we hypothesized that Cdkn1b knockdown would correspond to greater leukemia stem cell (LSC) activity, which may
explain its accelerated phenotype. To this end, we used fresh
c-Kit+ MLL-AF9 leukemic splenocytes from moribund animals to
quantify colony-forming cells (CFCs) in vitro and the frequency
of LSC by limiting cell dilution transplantation in vivo (Fig. 3 C).
While MLL-AF9 cells freshly transduced with Cdkn1b or NT control shRNA exhibit no differences in clonogenicity or replating
potential (Fig. S3 D), c-Kit+ Cdkn1b-knockdown MLL-AF9 leukemic splenocytes from moribund mice formed significantly
greater numbers of colonies than shRNA control (Fig. 3 D). Sublethally irradiated mice transplanted with limiting numbers of
c-Kit+ Cdkn1b or NT control shRNA expressing MLL-AF9 AML
cells were monitored for survival over 60 d (Fig. S3 E-G), at which
point LSC frequencies were estimated using the ELDA web tool
(Hu and Smyth, 2009). Two independent Cdkn1b-knockdown
tumors had LSC frequencies of 1/152.6 and 1/84.7, which were
statistically significant from the frequency of LSCs (1/360.9) in
NT control MLL-AF9 AML (Fig. 3 E). Thus, suppression of Cdkn1b
increases the number of MLL-AF9 LSCs.
Cdkn1b-knockdown leukemia also showed down-regulation of a mature hematopoietic cell gene set (Fig. 3 F; Ivanova
et al., 2002). To experimentally validate this observation, we
performed flow cytometry to examine myeloid differentiation
markers CD11b and Gr1 on Cdkn1b-knockdown compared with
NT control MLL-AF9 leukemic splenocytes. As previously described, MLL-AF9 AML is characterized by immunophenotypically mature CD11b+Gr1+ granulocyte/monocyte progenitor
(GMP)–like cells (Fig. 3 G; Krivtsov et al., 2006; Somervaille
and Cleary, 2006). In agreement with the gene expression data,
Cdkn1b-knockdown was associated with significantly reduced
expression of CD11b on MLL-AF9 leukemic GMPs compared
with NT control (Fig. 3 H and Fig. S3, H and I). Together, these
data suggest lowering p27Kip1 levels is important for restricting
myeloid differentiation and expanding LSCs within the MLL-r
leukemic state.
In agreement with Cdkn1b-knockdown augmenting LSC activity, GSEA analyses showed increased expression of the ESC
core gene set (Wong et al., 2008), and an independent gene ontology analysis revealed significant enrichment in cell proliferation
and apoptosis processes (Fig. S3 J). It is possible that either similar proliferation rates of ESC and of MLL-AF9 LSC (Somervaille
et al., 2009), or indirect effects on Myc (Kim et al., 2010), may
explain the enrichment of ESC-like gene sets within cancer-derived gene expression signatures. To this end, we bioinformatically dissected Myc-regulated genes (Kim et al., 2008, 2010) from
the ESC core gene set (Table S2; Wong et al., 2008). We also used
a previously published ESC gene set with cell cycle annotations
removed (Somervaille et al., 2009). Importantly, Cdkn1b-knockMeyer et al.
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down cells were significantly enriched for ESC core gene sets that
were Myc independent or with cell cycle annotations removed
(Fig. S3, K and L; and Table S2; Somervaille et al., 2009). Together,
these data suggest that repression of the miR-196b target Cdkn1b
enhances an ESC-like transcriptional program in leukemia cells,
and that this gene expression program extends beyond known
Myc and cell cycle effects. Altogether, these results suggest that
p27Kip1 regulates (1) expression of an ESC core gene set (Wong et
al., 2008), (2) LSC activity/clonogenicity, and (3) the differentiation of MLL-AF9 leukemic progenitors.
p27Kip1 interaction with cyclin–CDK complexes
regulates ESC-like gene expression, MLL-r leukemia
differentiation, and survival
Given the association of Cdkn1b-knockdown MLL-AF9 leukemia
gene signature with that of AML with poor outcomes (Table S2;
Somervaille et al., 2009), we posited that Cdkn1b may have clinical utility in MLL-r AML. As proof of concept, we force expressed
Cdkn1b and a selectable marker (ZsGreen) in MLL-AF9 leukemic
splenocytes. An empty vector (EV) served as control. ZsGreen+
cells were FACS-sorted and plated in methylcellulose colony assays or transplanted into recipient mice (Fig. 4 A, schematic).
p27Kip1 overexpression significantly inhibited MLL-AF9 colony
formation in vitro (Fig. 4 A). In vivo, p27Kip1 overexpression
significantly delayed survival compared with EV control, but
all mice succumbed to AML (Fig. 4 B). However, leukemic splenocytes harvested from mice transplanted with Cdkn1b-overexpressing MLL-AF9 cells were completely devoid of ZsGreen+
marker expression (black lines) as compared with EV control
mice (Fig. 4 C, green lines). Moreover, immunoblot analyses revealed similar p27Kip1 protein levels in leukemic splenocytes from
Cdkn1b or EV control MLL-AF9 transplanted mice (Fig. 4 C). In
sum, p27Kip1 overexpression is not compatible with MLL-AF9 leukemogenesis in vitro and in vivo.
To understand how p27Kip1 exerts anti-leukemic effects, we
expressed either WT p27Kip1 (WT p27) or two p27Kip1 mutants
in primary murine MLL-AF9 leukemia. Mutation of p27Kip1 at
Ser10 to Ala (S10A) mimics the dephosphorylation of p27Kip1 at
this residue inhibiting its nuclear export and promoting assembly into cyclin–CDK complexes (Besson et al., 2006). Thus, the
S10A mutation increases p27Kip1-mediated cell cycle inhibition.
Conversely, mutation of the amino acids required for p27Kip1
interaction with cyclins (R30A and L32A) and CDKs (F62A and
F64A) generates the p27Kip1 (CK−) mutant. The CK− mutant abolishes p27Kip1-mediated cell cycle inhibition (Besson et al., 2006).
Expression of WT p27 or the S10A mutant induced G1 cell cycle
arrest (Fig. S4 A) and monocytic differentiation (Fig. 4 D) of
MLL-AF9 leukemic blasts as compared with EV. The CK− mutant
expressing cells were similar to EV cells (Fig. 4 D), suggesting
that cell cycle and differentiation effects are linked. Additionally,
ESC-like genes Lmnb1, Msh2, and Prmt1 (from Fig. 3 B and Fig.
S3, F and G) were significantly repressed by WT p27 expression,
whereas expression of c-Myc and Hadh was unchanged (Fig. 4 E).
The CK− mutant abrogated repression of Msh2 and Prmt1, while
repression of Lmnb1 was observed in all groups (Fig. 4 E, compare CK− with EV). This suggests that p27Kip1 interaction with
cyclin–CDK complexes is important for the expression of a subJournal of Experimental Medicine
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Figure 3. miR-196b targets Cdkn1b to regulate leukemia stemness and differentiation programs in MLL-AF9 leukemia. (A) Heatmap of gene expression
in Cdkn1b shRNA-knockdown and NT-shRNA control leukemias. Hierarchical clustering of 113 differentially expressed genes showing greater than twofold
change in expression by RNA-seq analysis of NT-shRNA control (n = 2) or Cdkn1b shRNA (n = 2) expressing MLL-AF9 leukemic splenocytes. (B) GSEA plot
ranking ESC core gene set along descending fold change gene expression in Cdkn1b-knockdown (n = 2) versus NT control leukemias (n = 2) by RNA-seq.
Expression of the top subset of leading edge genes is shown. NES, normalized enrichment score. (C) Schematic illustrating in vitro colony forming assay and
in vivo limiting cell dilution transplantation assay to quantify functional stem cells from freshly isolated Cdkn1b shRNA and NT control MLL-AF9 leukemias.
(D) In vitro leukemic stem cell analysis. Average CFU ± SEM from c-Kit+ leukemic splenocytes from individual Cdkn1b shRNA (n = 3) or control shRNA MLL-AF9
moribund mice. Mean numbers of CFU ± SEM indicated below. A representative experiment is shown. Statistical significance evaluated by t test. *, P ≤ 0.05;
**, P ≤ 0.01. (E) In vivo quantitation of leukemic stem cells by limiting dilution. Sublethally irradiated mice transplanted with a cell dose range of 1,000, 600,
300, 100, and 30 cells (n = 6 mice/dose) were followed for 90 d. LSC frequencies and statistical comparisons for pairwise differences in active cell frequencies
(table and log-fraction plot) between Cdkn1b-knockdown groups and NT control group were calculated by ELDA software (see Fig. S3 [E–G] for corresponding
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set of ESC-like genes regulated in response to p27Kip1 signaling
in leukemia cells. Moreover, WT p27 and S10A, but not CK− expression, significantly reduced MLL-AF9 clonogenicity (Fig. 4 F).
Next, we extended these analyses into three human MLL-r AML
cell lines with differing levels of miR-196b expression (Fig. S4 B).
Similar to murine AML, human AML cells expressing WT p27
and the S10A mutant, but not the CK− mutant, underwent G1 arrest (Fig. S4 C) and were counter-selected over time (Fig. 4 G). Altogether, these data demonstrate that elevating p27Kip1 has tumor
suppressive activity in both human and murine MLL-r AML at
least in part through coordinated induction of growth arrest and
differentiation, and repression of ESC-like gene expression.
p27Kip1 as a therapeutic target in MLL-r leukemia
Given that Cdkn1b overexpression had anti-leukemic effects
(Fig. 4), we next tested whether disruption of mechanisms regulating endogenous p27Kip1 protein expression and turnover would
also negatively affect MLL-AF9 leukemogenicity. First, we disrupted the miR-196b direct interaction with Cdkn1b mRNA using
sequence-specific miRNA target site blockers (TSB) constructed
with locked nucleic acid (LNA) chemistry (Petersen and Wengel,
2003; Fazi et al., 2005; Ceppi et al., 2009; Wynendaele et al., 2010;
Dajas-Bailador et al., 2012). Primary murine MLL-AF9 leukemia
cells were treated with TSB sequences homologous to the validated miR-196b binding site in the Cdkn1b 3′UTR (Fig. 1 D), as
well as anti-miR-196b-5p and scrambled nontargeting control
LNAs. Anti–miR-196b (positive control) or any of the miR-196bCdkn1b TSB treatments significantly reduced colony formation
(Fig. 5 A) accompanied by derepression of p27Kip1 protein expression compared with NT control LNA (Fig. 5 A, immunoblot).
These data indicate that the miR-196b/Cdkn1b signaling axis is
important to maintain MLL-AF9 clonogenic capacity.
In addition to miR-196b regulation, the ubiquitin-proteasome pathway regulates p27Kip1 protein expression. The F-box
protein S-phase kinase-associated protein 2 (Skp2) is the substrate recognition subunit of the SCF E3 ubiquitin ligase complex
(SCFSkp2) that targets proteins including p27Kip1 for proteasome
degradation (Carrano et al., 1999; Sutterlüty et al., 1999; Tsvetkov
et al., 1999; Kossatz et al., 2004). Thus, an orthogonal way to elevate p27Kip1 therapeutically would be to block SCFSkp2-mediated
protein turnover. SLZ P1-41 is a small molecule inhibitor of the
SCFSkp2 E3 ubiquitin ligase complex that blocks Skp2–Skp1 binding. Previously, SLZ P1-41 was shown to decrease ubiquitination
of SCFSkp2 targets (including stabilization of p27Kip1) and delay
prostate tumor growth in vivo (Chan et al., 2013). Treatment of
human MLL-r AML cell lines THP1, MOLM13, and MV4;11 with
SLZ P1-41 resulted in significant AML cell death in a dose-dependent manner (Fig. 5 B). In contrast, the Cdc34 E2 ubiquitin enzyme inhibitor CC0651 (Ceccarelli et al., 2011) had no effect (data

not shown). Despite differing sensitivities of AML cells to SLZ
P1-41, the lowest dose that elicited a cell-killing effect was associated with increased p27Kip1 protein levels in all cases (Fig. S5 A).
While there are likely multiple Skp2-regulated proteins that may
affect AML cell death, these results suggest that accumulation
of p27Kip1, through disruption of miR-196b and/or Skp2 activity,
represents a potential new therapeutic opportunity for AML.
Inhibitors of Menin/MLL (Ml-1), BET family (IBET-151), and
CDK4/6 (Palbociclib) are currently being tested for MLL-r AML
in the clinic. Given encouraging results with SLZ P1-41, we sought
to identify a more potent SCFSkp2 inhibitor with a lower relative
IC50 that could be used to compare the effects of chemically perturbing p27Kip1 protein levels to the effects of existing small-molecule therapeutics. To that end, we evaluated N-(5-(pyridin-3-yl)
quinolin-8-yl)-3-(trifluoromethyl)benzenesulfonamide, referred to as 22d (Singh et al., 2015). 22d is a potent (0.17 µM IC50)
inhibitor of the Skp2-Cks1 interaction that is required for SCFSkp2
ubiquitination of p27Kip1 (Ganoth et al., 2001; Spruck et al., 2001).
First, we performed dose titrations of 22d measuring cell viability after 3 d of treatment to determine the relative IC50 doses of 3,
0.9, and 0.6 µM 22d in THP1, MV4;11, and MOLM13, respectively
(data not shown). Notably, p27Kip1 protein levels were increased
in a dose-dependent manner upon 22d treatment in all three
AML cell lines (Fig. S5 B). Next, we independently titrated inhibitors of Menin/MLL (Ml-1), BET family (IBET-151), and CDK4/6
(Palbociclib) to identify the relative IC50 for each drug on THP1,
MOLM13, and MV4;11 human AML cells (data not shown). Third,
AML cells were treated with three to four doses of Ml-1, IBET151, or Palbociclib with and without 22d using a dose range that
spanned the relative IC50 dose determined for each drug in each
AML cell line. After 3 d, cell viability was measured relative to
vehicle control treated cells (Fig. 5, C–E; and Table S3). Synergy
with 22d plus IBET-151 was observed in THP1 and MV4;11, but not
MOLM13 cells. Conversely, 22d plus Palbociclib showed synergy
in THP1, but not MV4;11 or MOLM13 cells. Overall, 22d plus the
Menin/MLL inhibitor Ml-1 showed the most consistent synergistic effects across all cell lines tested (Table S3). Thus, inhibiting
Skp2-Cks1 interaction may be a complementary target to those
currently under investigation. Finally, we determined whether
primary human MLL-r AML are sensitive to 22d. After 3 d in vitro
treatment with 22d, we observed growth inhibition of MLL-r
AML patient samples (Fig. 5 F and Table S3), at 22d concentrations similar to those required to inhibit MLL-r AML cell lines.

Discussion

Target predication algorithms can be useful, cost-effective tools
to identify miRNA target interactions. However, predication algorithms alone are biased for canonical miRNA seed pairing, pre-

survival curves). Statistically significant differences in LSC frequencies of NTsh control (1/360.9) versus Cdkn1bsh1 (1/152.6); *, P = 0.042 and NTsh control
(1/360.9) versus Cdkn1bsh2 (1/84.7) ***, P = 0.001. (F) GSEA plot ranking mature hematopoietic cells gene set along descending fold change gene expression
in Cdkn1b-knockdown versus NT control leukemias by RNA-seq (n = 2/group). Expression of the top subset of leading edge genes is shown. (G) Leukemic GMP
gating strategy: CD11b+Gr1+ lineage negative (Lin−, red), Lin−c-Kit+ (LK, orange), and LK CD34+CD16/32+ granulocyte monocyte progenitor gate (GMP, green).
(H) Flow cytometric validation of differentiation status. Representative flow plots (left) and average percentage of CD11bhi and CD11blo leukemic GMP-gate
populations ± SEM (right) from spleens of moribund Cdkn1b shRNA or control NT shRNA MLL-AF9 mice (n = 3/group). *, P < 0.05 for CD11bhi and CD11blo GMP
in Cdkn1b shRNA versus NT shRNA by two-way ANOVA.
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Figure 4. Cdkn1b/p27Kip1 suppresses MLL-r leukemia in a cyclin–CDK-dependent manner. (A) Top, schematic of CFU and transplantation of ZsGreen+
sorted Cdkn1b-ZsGreen (Cdkn1b) or EV-ZsGreen (EV) control expressing MLL-AF9 leukemia cells. Bottom, average number of colonies ± SEM (n = 3 replicates/
group). Mean CFU numbers ± SEM indicated below bar graph. **, P ≤ 0.01 by t test. Immunoblot analyses of p27 performed on cells from CFU assays with
β-actin as loading control. A representative of two independent experiments is shown with similar results. (B) Kaplan-Meier survival curve of mice transplanted
with ZsGreen+ Cdkn1b overexpressing MLL-AF9 cells (n = 6/group). Significant differences in survival evaluated by Log-rank (Mantel-Cox) test; *, P ≤ 0.05.
(C) Counter selection of p27 overexpression in vivo. Flow cytometric analyses for ZsGreen+ expression in EV (green lines) and Cdkn1b-overexpressing (black
lines) MLL-AF9 leukemic splenocytes from moribund mice. Three representative mice/group are shown. Immunoblot analysis of p27 with β-actin as loading
control (n = 3 mice/group). (D–F) Functional dissection of p27 activity. WT p27Kip1 (WT p27), nuclear localized p27Kip1 (S10A; increased cell cycle inhibition), or
CDK-binding domain mutant p27Kip1 (CK−; no cell cycle inhibition) were expressed via lentiviral vectors in murine MLL-AF9 leukemic splenocytes. EV vector
served as control. Cells were FACS sorted for ZsGreen+ 48 h after transduction and prepared for cytospin (D), RNA (E), or plated in CFU assay (F). Representatives of two independent experiments with similar results is shown. (D) Cytologies of ZsGreen+ EV, WT p27, S10A, and CK− expressing MLL-AF9 cells were
visualized with Wright Giemsa stain and imaged at 60× magnification. Bars, 10 µm. (E) RNA extracted from ZsGreen+ EV, WT p27, S10A, and CK− MLL-AF9
cells was examined by RT-qPCR for changes in c-Myc expression as well as representative non–Myc-regulated (Ccnd2, Hadh, Lmnb1, and Msh2) and ESC core
genes (Prmt1; n = 2 replicates/group; from Fig. S3, K and L). Expression was compared with Sdha as loading control and is graphed as average relative to EV ±
SEM. Statistical significance was evaluated for each gene by two-way ANOVA Holm-Sidak multiple comparisons test. (F) Equal numbers of ZsGreen+ EV, WT
p27, S10A, and CK− expressing MLL-AF9 leukemic splenocytes were plated in triplicate in methylcellulose. The average number colonies ± SEM enumerated
after 7 d in methylcellulose is shown for three technical replicates with mean CFU ± SEM indicated below. A representative of two independent experiments
is shown. Statistical significance was evaluated by one-way ANOVA Holm-Sidak multiple comparisons test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤
0.0001. n.s., not significant. (G) Human AML cell lines are organized according to their levels of miR-196b expression (lowest to highest, red gradient triangle;
see also Fig. S4 B). The relative frequency of ZsGreen+ EV, WT p27, S10A, or CK− transduced THP1, MV4;11, and MOLM13 cells measured over time are shown
as relative to the proportion of ZsGreen+ cells at the initial time point 48 h post-transduction. A representative experiment is shown.

dict thousands of targets for a given miRNA, and have no cellular
context. These shortfalls often lead to a high error rate when attempting to validate miRNA binding and functional importance
in a biological system. With the use of experimental endogenous
miRNA–mRNA target discovery methods, including biotinylated
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miR-mimic pulldown, HITS-CLIP, PAR-CLIP, and TAP-Tar, it is
now believed that noncanonical target recognition (i.e., seedless)
may play a large role in miRNA-mediated regulation, binding can
occur outside of the 3′UTR, and target regulation is often context specific. We identified miR-196b targets in human MLL-r
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Figure 5. RNAi disruption of miR-196b activity or pharmacologic inhibition of SCFSKP2 elevate p27Kip1 and inhibit human AML growth. (A) MLL-AF9
leukemic splenocytes were treated with indicated LNA and plated in triplicate for CFU assays. The sequences of the LNAs coded for a scramble nontargeting
control (NT), homologous sequence to miR-196b-5p (anti-196b), or three variant target site–blocking (TSB1-3) LNAs designed with sequence homology to the
Cdkn1b 3′UTR miR-196b target binding site (miR196b:Cdkn1b). CFU results are shown as the average number of colonies ± SEM for each LNA in two independent
experiments (left), with mean CFU ± SEM indicated below. Statistical significance was evaluated by t test for anti-196b and TSB LNAs compared with NT control.
Immunoblots for p27 (right) were performed on LNA-treated CFU to detect target engagement with β-actin as loading control. (B) Average ± SEM percentage
of alive (AnnexinV−PI−) THP1, MV4;11, and MOLM13 human AML cells treated for 3 d in duplicate with the indicated amounts (μM) of SLZ P1-41 (squares) or
equivalent volume of DMSO control (circles). Statistical significance was evaluated for each cell line by multiple unpaired t tests Holm-Sidak multiple testing
correction. *, P ≤ 0.05; **, P < 0.01. Relative miR-196b expression indicated by triangular color scale (see also Fig. S4 B). (C–E) Cell viability heat maps of THP1
(C), MV4;11 (D), and MOLM13 (E) cells treated for 3 d with single drugs or combinations of 22d, IBET-151, Ml-1, or Palbociclib. Color scale is denoted in C. A
representative of at least two experiments with similar results is shown for each. See Table S3 for analyses of drug synergies. (F) Primary human MLL-r AML
patient samples (n = 6) were treated with increasing concentrations of 22d. Cell viability was measured by MTS for all doses after 3-d 22d treatment.

AML cells using an experimental biotinylated miR-mimic pulldown approach, which identified candidate miRNA target genes
that are not predicted by one or even any prediction algorithm.
Thus, the use of an experimental approach can identify novel,
disease-relevant miRNA targets.
miRNA are universally down-regulated in cancers compared
with normal tissues (Lu et al., 2005), perhaps because miRNA
can function as tumor suppressors, or miRNA biogenesis may
be tumor suppressive (Kumar et al., 2007; Chang et al., 2008).
However, mutations in DICER1 have been identified in human
cancers, and Dicer1 haploinsufficiency is more permissive to tumorigenesis than either WT or Dicer1 knockout in mice (Kumar
et al., 2009). Thus, some degree of miRNA signaling might be
required for oncogenesis. Indeed, miR-196b provides an example of a miRNA signaling network important for the stemness
and survival of MLL-AF9 leukemia. Functional screening of a
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subset of direct miR-196b targets during leukemia expansion in
vivo revealed shRNA-mediated repression of targets were largely
counter-selected or unchanged, yet repression of some targets
(∼25%) exhibited significant pro-leukemic effects. Thus, miR196b signaling balances both tumor growth and tumor-suppressive effects that can be functionally dissected in vivo to identify
which are important for oncogenic miRNA signaling.
We find Cdkn1b (p27Kip1) is one of the top miR-196b targets consistently bound by miR-196b in several different target-validation methods. While miRNA buffer normal stem
cell maintenance and myeloid differentiation (Emmrich et al.,
2014; Lechman et al., 2016), our studies extend the functional
requirement for miRNA buffering to malignant stem cell biology. Cdkn1b-knockdown by shRNA, which mimics miR-196b
activity, cooperates with MLL-AF9 to accelerate leukemogenesis, increases LSC output, and signals a poor prognosis gene
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signature. Conversely, specific disruption of the miR-196b-Cdkn1b target interaction increases p27Kip1 levels, significantly
reducing MLL-AF9 clonogenicity. We note that the effect of Cdkn1b-knockdown on MLL-AF9 leukemia maintenance is dissimilar to germline deletion of Cdkn1b (Zhang et al., 2013). Germline
deletion of Cdkn1b impacts proliferation of normal hematopoietic progenitors (Cheng et al., 2000), a population capable of
transformation by MLL-AF9 (Krivtsov et al., 2006). Thus, our
data provide an important distinction between the effects of (1)
complete deletion of Cdkn1b on MLL-AF9 leukemia initiation
(Zhang et al., 2013), (2) sustaining low-level p27Kip1 expression
in leukemia stem cell maintenance, and (3) derepressing p27Kip1
levels triggering anti-leukemic effects. Altogether, our studies
support the conclusion that miR-196b activity functions to regulate the levels of its targets, such as tumor suppressor p27Kip1,
for leukemia stem cell maintenance and survival.
Repression of Cdkn1b (p27Kip1) was anticipated to influence
cell cycle and apoptosis since these p27Kip1 functions are well described (Polyak et al., 1994; Toyoshima and Hunter, 1994; Katayose
et al., 1997; Wang et al., 1997); however, our studies also uncovered increased expression of genes associated with an ESC-like
transcriptional program. Notably, Cdkn1b-knockdown leukemia
gene expression was enriched for the ESC gene set with cell cycle
annotations removed (Somervaille et al., 2009). This ESC core
signature is distinct from an adult stem cell signature (Wong et
al., 2008) and is enriched in a variety of cancers with high frequencies of cancer stem cells, including functionally validated
MLL-AF9 LSCs (Somervaille et al., 2009). Whether or not an
ESC-like program is responsible for cancer stem cell self-renewal
remains controversial. Oncogenic c-Myc activity might specify
ESC-like signatures in cancer (Kim et al., 2010); however, we find
that Cdkn1b-knockdown leukemia was still enriched for a c-Myc–
independent ESC-core gene set. Thus, at least part of p27Kip1 ESC
programming is c-Myc independent, in agreement with our finding that forced expression of p27Kip1 did not affect c-Myc transcript levels. Instead, forced expression of p27Kip1 significantly
repressed the expression of a subset of these ESC-like genes. In
sum, these data support an MLL-AF9-miR-196-Cdkn1b pathway
that controls leukemia stem cell activity through the regulation
of ESC-like core genes (independent of c-Myc or cell cycle).
Failure to eradicate leukemia stem cells within minimal residual disease leads to relapse. Consequently, AML subtypes with
high frequencies of LSC are associated with poorer outcome (van
Rhenen et al., 2005; Ghiaur et al., 2012; Terwijn et al., 2014). Thus,
pathways that maintain LSC self-renewal, survival, or suppress
differentiation represent important therapeutic opportunities
for the treatment of AML. Our work illustrates how unbiased
global dissection of oncogenic miRNA signaling can be exploited
to identify actionable LSC-relevant targets. MLL-AF9 and its
downstream target HoxA9 transactivate miR-196b expression
(Popovic et al., 2009; Velu et al., 2014). Here we define a unique
subset of miR-196b direct targets involved in transcriptional
and cell cycle processes that help to explain oncogenic miR-196b
activity. Our work uncovered p27Kip1 as a potential therapeutic
target for the MLL-r AML subtype. We find that inhibiting the
E3 ubiquitin ligase activity of SCFSkp2 complexes results in elevation of p27Kip1 protein levels (Chen et al., 2008a; Ceccarelli et
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al., 2011; Chan et al., 2013), and that MLL-r AML are sensitive
to Skp2 inhibitors. There should be a significant therapeutic
window for this approach, as genetic deletion of Skp2 in mice
decreases HSC quiescence and increases HSC proliferation without adversely affecting HSC long-term repopulating potential
(Wang et al., 2011). Finally, we identify that Skp2 inhibition acts
synergistically with Menin/MLL, BET, or CDK4/6-targeted therapeutics in AML contexts where treatment as single agents are
less effective. For example, we observe THP1 cells are relatively
resistant to Palbociclib as compared with MV4;11 or MOLM13
cells. However, cotreatment with Palbociclib and the Skp2-Cks1
inhibitor 22d synergize to induce growth arrest and/or cell death
of THP1 AML cells, but not MV4;11 or MOLM13 cells. In conclusion, we have elucidated a critical miRNA pathway that can be
exploited therapeutically to tip the balance from tumor growth
to tumor suppression. Our study establishes an experimental
approach for future studies that combines in vitro miRNA target
identification and in vivo shRNA screening to identify clinically
important miRNA targets to better understand miRNA signaling
pathways in cancer.

Materials and methods

Transgenic animals, mouse maintenance, and murine studies
All animal studies were approved by and performed in compliance with the Institutional Review Board Committee on Animal
Research at Cincinnati Children’s Hospital Medical Center (CCH
MC). All animal procedures were conducted in accord with the
Institutional Animal Care and Use Committee at CCHMC. Mouse
strains used in viral transduction and transplantation studies
included CD45.2+ C57BL/6-Ly5.2 (JAX and Charles River) and
CD45.1+ C57BL/6-Ly5.1 (Charles River and CCHMC Comprehensive Mouse Core). All transplant recipient mice were male
between 1–3 mo of age. Murine CD45.1+ MLL-AF9 leukemia was
a gift from N. Zeleznik-Le (Loyola University Chicago, Chicago,
IL). MLL-AF9 leukemic splenocytes were expanded in house by
transplantation into eight recipient mice. Single cell suspensions
from all moribund mouse spleens were pooled, red blood cells
(RBCs) lysed by ammonium-chloride-potassium (ACK) buffer
(Gibco) and archived as ∼15 × 106 cell aliquots in 10% DMSO liquid nitrogen frozen to create a homogeneous stock from which
all shRNA and gene overexpression studies were performed. For
shRNA and gene overexpression studies, the replicate hairpins
per gene and matched controls were performed simultaneously,
and no blinding was used when recording animal survivals.
For independent shRNA hairpin validations and gene overexpression studies, no statistical method was used to predetermine sample size.
Human AML cell line validation
For cell line validation, DNA was harvested from our THP1,
MV4;11, and MOLM13 cells actively growing in culture using the
Blood and Tissue kit (Qiagen). DNA was sent to Genetica DNA
Laboratories, who performed the SNP analyses. ATCC database
search for the SNPs reported in our human AML cell lines match
with 100% identity to the SNPs in the correctly corresponding
human AML cells at ATCC (Table S3).
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Biotinylated miR mimic pulldown
The biotinylated miRNA mimic–mRNA target pulldown approach was adapted from Lal et al. (Lal et al., 2011) with modifications. miRIDIAN miRNA mimics hsa-miR-196b and C. elegans
cel-67 miRNA control were purchased from Dharmacon (ThermoFisher Scientific) with a biotin modification at the 3′ end of
the mature/anti-sense strand (Bi-miR-196b and Bi-cel-67). THP1
cells were a gift from J. Parentesis (CCHMC), and were SNP verified by Genetica DNA Laboratories (see Supplemental material).
HEK293T cells were cultured in DMEM (ThermoFisher Scientific) containing 10% heat-inactivated FBS (Atlanta Biologics),
Pen-Strep (ThermoFisher Scientific), and l-Glutamine (ThermoFisher Scientific). For Bi-miR pulldowns, 0.2 × 106 HEK 293
cells were plated overnight then cotransfected the following day
with 100 nM biotinylated miRNA mimics and 0.5 µg/ml GFPMax (Lonza) with CaCl2 BBS. THP1 cells were cultured in RPMI
1640 (ThermoFisher Scientific) containing 20% heat-inactivated
FBS (Atlanta Biologics), Pen-Strep (ThermoFisher Scientific),
and l-Glutamine (ThermoFisher Scientific). Cells were maintained in liquid culture at subconfluency at low passage at 37°C
in 5% CO2. For Bi-miR pulldowns, 106 THP1 cells were cotransfected with 100 nM biotinylated miR mimics and 0.5 µg/ml GFPMax by electroporation using Amaxa Nucleofector 4D and cell
line SG kit (Lonza) according to manufacturer instructions.
24 h after transfection, cells were lysed on ice in a cytosolic
lysis buffer RLN (Qiagen) with 1× HALT protease inhibitor tab
(Roche), RNaseI (Ambion), and 1 mM DTT (Sigma). Nuclei were
pelleted at 10,000 g for 10 min at 4°C and discarded. 10% of cytosolic lysates were mixed with TriZol LS (Ambion) as “Input”
control then frozen at −80°C, while the remaining lysates were
subjected to “Pulldown” by mixing with M-280 Dynabeads (Invitrogen) for 4 h rotating at 4°C. Dynabeads were prepared in advance for RNA use according to manufacturer instructions, then
rinsed in cold lysis buffer and blocked with rotation at 4°C for
2 h with yeast tRNA (Invitrogen) and BSA (Invitrogen). After the
pulldown incubation, beads were washed on a magnetic stand
three times with ice-cold wash buffer (Nonne et al., 2010) for 3
min rotating at 4°C. After the last wash beads were resuspended
in 0.75 ml TriZol LS and brought to 1 ml with nuclease free water
(ThermoFisher Scientific) then frozen at −80°C. Isolated RNAs
of both input and pulldown fractions were examined for target
enrichment by TaqMan RT-qRCR using the delta Ct method as
follows in Eq. 1 and Eq. 2 to calculate pulldown enrichment ratios.
Enrichment = 2-ΔΔCt; Eq. 1 = ΔCt; Eq. 2 = ΔΔCt.
Pulldown [ Ct  Target Gene – Ct  SDHA] and
		Input [
 Ct  Target Gene – Ct  SDHA]

(1)

		[ ΔCt  Target Pulldown – ΔCt  Target Input]

(2)

RNA extraction, TaqMan quantitative PCR gene, and miRNA
expression analyses
RNA was extracted using TriZol or TriZol LS (Ambion) as previously described (Meyer et al., 2009). Total RNA was converted into cDNA using the High Capacity cDNA Archive kit
(Life Technologies) for standard gene expression analyses and
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or with miRNA TaqMan RT assays for hsa-miR-196b-5p, mmumiR-196b-5p, hsa-miR-196a-5p, and mmu-miR-196a-5p (Life
Technologies) according to manufacturer instructions. All
gene and miRNA expression were quantified using TaqMan
assays (Life Technologies) with the 2× Universal TaqMan Master Mix (Life Technologies) according to the manufacturer
instructions on the StepOne Plus Instrument (Applied Biosystems, Inc.) using equal amounts of starting cDNA. Standard
inventoried gene expression TaqMan assays recommended by
the manufacturer (Life Technologies) for best coverage were
purchased when available. For human gene expression assays:
CDKN1B (NM_004064.3), SPTSSA (NM_138288.3), HOXA7
(NM_006896.3), SLC9A6 (NM_001042537.1, NM_001177651.1,
NM_006359.2), MDM4 (NM_001204171.1, NM_001204172.1,
NM_001278516.1, NM_001278517.1, NM_001278518.1, NM_
001278519.1, NM_002393.4), TAF5L (NM_001025247.1, NM_
014409.3), ZCCHC9 (NM_001131035.1, NM_001131036.1,
NM_032280.2), PHC2 (NM_004427.3, NM_198040.2), PHC3
(NM_024947.3),
TMEM184C
(NM_018241.2),
HOXA9
(NM_001277238.1, NM_010456.3), SDHA (NM_004168.2). For
mouse gene expression assays: HoxA7 (NM_010455.2), HoxB9
(NM_008270.2), and Meis1 (NM_001193271.1, NM_010789.3),
Phc2 (NM_001195083.1, NM_001195130.1, NM_018774.4), Taf5l
(NM_133966.2), Zcchc9 (NM_145453.2), Cdkn1b (NM_009875.4),
Sptssa (NM_134054.2), Slc9a6 (NM_172780.3), Mdm4
(Mm.426531), c-Myc (NM_001177352.1, NM_001177353.1,
NM_001177354.1, NM_010849.4), Ccnd2 (NM_009829.3), Hadh
(NM_008212.4), Lmnb1 (NM_010721.2), Msh2 (NM_008628.2),
Prmt1 (NM_001252476.1, NM_001252477.1, NM_019830.3,
NR_045521.1), and Sdha (NM_023281.1). For human mature
miRNA expression assays (Life Technologies): hsa-miR-196b-5p,
hsa-miR-196a-5p, and RNU6B (NR_002752). For mouse mature miRNA expression assays (Life Technologies): mmu-miR196b-5p, mmu-miR-196a-5p, and U6 snRNA (NR_004394).
Gene expression data were analyzed using the comparative Ct
method (2-ΔΔCt). SDHA and RNU6B served as loading controls.
For Bi-miR pulldown validation assays the fold change pulldown
and inputs (Eq. 1) was calculated (see Biotinylated miR mimic
pulldown method).
Affymetrix microarray and data analyses
Microarrays were performed that the CCHMC Microarray Core
Facility. In brief, miR mimic pulldown and input control RNA
samples were analyzed on an Agilent Bioanalyzer with a RNA
integrity number >8.0 were selected for microarray processing. 550–1,000 pg of matched input and pulldown RNA samples
from three independent THP1 experiments and one HEK293
experiment were processed using the Ovation Pico WTA System V.2 (Nugen) and hybridized to Human Gene 1.0 ST arrays
(Affymetrix). For HEK293 and THP1 pulldowns, gene expression
was obtained using the RMA algorithm output from the GCOS
Affymetrix software with a raw value cut-off of 5 in pulldown
samples. The Bi-miR-196b input and pulldown samples were
normalized separately to show change relative to the Bi-cel-67
control samples. Results were visualized in GeneSpring and AltAnalyze version 2.0.9 for any Ensembl version 72 gene aligning probe sets transcript clusters (Salomonis et al., 2009, 2010;
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Emig et al., 2010). miR-196b target genes are reported for independent pulldowns with a twofold increase in the miR-196b
pulldown fractions compared with the cel-67 pulldown controls.
(Fig. 1 B and Table S1). Venny 2.0 (Oliveros, 2015) or InteractiVenn (Heberle et al., 2015) was used to overlap pulldown target
lists with target site computational prediction algorithms PITA
(Kertesz et al., 2007), miRanda (Enright et al., 2003; John et al.,
2004; Betel et al., 2008), TargetScan7.0 (Lewis et al., 2003, 2005;
Agarwal et al., 2015), and DIANA (Maragkakis et al., 2009a,b;
Papadopoulos et al., 2009) to aide identification of pulldown
targets for the shRNA screen (Table S1).
Target site sequences, cloning, and luciferase reporter assays
Following the miRNA target interaction principles demonstrated by Kertesz et al. and Ellwanger et al. (Kertesz et al., 2007;
Ellwanger et al., 2011), a 22-nucleotide (nt) target site was identified beginning with minimal seed pairing (6 consecutive nt) and
extending the natural length of the targeting miRNA region of
homology in the mRNA target. An additional 3 nt flanking at the
5′ end and 15 nt flanking the 3′ end of the full-length (22 nt) target
site for a total of 40 nt. We used two different approaches to clone
target sites into the psiCHECK2 Dual Luciferase reporter vector
(Promega). All target site inserts were sequence verified at the
CCHMC sequencing core.
Either miR-196b target sites sequences (listed below) were ordered as double stranded DNA (dsDNA) gblocks from IDT (Integrated DNA Technologies) with 24 nucleotide overhangs on both
5′ (5′-CGAGCAGTAATTCTAGGCGATCGC-3′) and 3′ (5′-TCGAGC
CCGGGAATTCGGTTAAAC-3′) ends homologous to the 5′ and 3′
ends of the psiCHECK2 vector (Promega) cut with the Xho1 restriction enzyme (New England Biolabs). The target site gblocks
were cloned into the Xho1 site at the 3′ end of Renilla Luciferase
in psiCHECK2 dual luciferase reporter vector using Gibson Assembly (New England Biolabs).
CDKN1B: 5′-ATTATGCAATTAGGTTTTTCCTTATTTGCTTCATTG
TACTACCTGTGTATATAGTTTTTACCTTTTATGTAGCACATAAA-3′.
PHC2: 5′-ACTTCTT TGCCTATAAATCTTCCTAGCAGCAAT
TTG T TG AGC TAC C TG AGG AGG AGG C AG G GC AGA A AG G GC
GAGGGCCTGCC-3′.
SLC9A6-1: 5′-TTGTAAAATTTGCACATGTGATTGTGAAGA
AAT T TG TAC TAC C TA A AA G TC C CA G TG C AT G TC T CT G AA
TGTGTAAGCTA-3′.
SLC9A6-2; 5′-TTAT TCAAGT TGTAAAAGGTTATACAATAA
TTT A AC A AC TAC C TT T TT TAT T CT G TC G GG T TA C TG ACC
TCACTTTATGT-3′.
WDR75 : 5′-AAA A AC TAA ACG A AA C TT TAG AGA ATG AGC
TGG TAC A AC TAC C CT TAA C AG A AA ACA TAC C CG C AA T TA
GTGAGCTTCTT-3′.
TAF5L : 5′-TAA C AA G TA C GT G GT C CG TCT C CA AGA AGA
CAG C TA C AA C TA C CT TAT C CG C TA C CT C CA A AG T GA C AA
CAATACTGCCCT-3′.
SPT S SA : 5′-TTG  TAT  TGT  T TT  T TT  TAA G GT  T TT  TAT  TCC
TTA A AT G TA A AA T GA C TA C CT A AT T TT T TG ATG TAA ATA
CATTAAATTCAA-3′.
ZCC H C9 : 5′-TGT TAA T TT T TG ATA ACA G CT AGC ACT ATC
ATG AGT TAC TAC C TC ATT G TT ACT T TC TAA ACC AGG C CC
GCTTCACGAGT-3′.
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Elsewise, miR-196b target sites sequences (listed below) were
synthesized as single stranded complimentary DNA strands
(Upper and Lower) with 5′ XhoI and 3′ NotI restriction sites on
the ends (Upper, XhoI/NotI 5′-TCGAG…GC-3′ and Lower, NotI/
XhoI 5′-GGCCGC…C-3′; ThermoFisher Scientific). Equimolar
amounts of the two strands were annealed before T4 DNA ligase
(New England Biolabs) mediated ligation to XhoI/NotI cut psiCHECK2 dual luciferase reporter vector (Promega).
HOXA7 :
5′-ACT ACC TAC T CC C CT A AA ACT ACC TAT
TTTGTGCTGGCTG-3′.
MDM4-1 :
5′-GAC G AT ATC C CC ACA C TG C CT ACC T CA
GAGCATAAATGCA-3′.
MDM4-2 : 5′-CAT G TT T TG ATC C TG ATG C TA C CT T TG
CTAAAAATGGCCA-3′.
PHC3-1 :
5′-TGA A AG G GC C TC ATC T CA C TA C CT C TC
TAAGGCCTCTAGC-3′.
PHC3-2 :
5′-AGG T TC T TC C TA C TT T TG C TA C CT A AG
TTTGCATTTTCTG-3′.
CDKN1B :
5′-CTT ATT T GC T TC ATT G TA C TA C CT G TG
TATATAGTTTTTA-3′.
The number of cells, transfection reagents, reporters, miR
mimics, and luciferase assay reagents were all titrated and optimized for use in 96-well format with the PerkinElmer EnVision plate reader with injectors. HEK293T cells were seeded in
regular growth medium, as described above, at 8 × 104 c/ml in
96-well plates. The following day cells were cotransfected with
miR mimics and luciferase reporter plasmids using DharmaFect
Duo (Dharmacon) according to manufacturer’s instructions with
the following final concentrations per well: 50 nM miR mimic
(nontargeting or miR-196b-5p purchased from ThermoFisher
Scientific), 50 ng of the indicated psiCHECK2 plasmid, 50 ng
pBlueScript plasmid (to bring total DNA to optimal recommended
range), and 0.4 µl DharmaFect Duo in a total volume of 100 µl
growth medium. Cells were incubated with transfection mixture
for 24 h, and then luciferase activity was measured using the Dual
Luciferase Assay System (Promega) according to manufacturer
instructions with the following modifications. Cells were lysed in
40 µl 1× Passive Lysis Buffer (Promega) for 15 min to 1 h at room
temperature, and then 30 µl lysate was transferred to a white
flat-bottom plate. The EnVision injectors were filled with LARII
and Stop+Glo (Promega) and the Dual Luciferase Assay protocol
dispensed 25 µl LARII, shake plate 1 s at 300 rpm, incubated 10 s,
read Firefly luminescence (400–700 nM), dispensed 25 µl Stop+Glo, shake plate 1 s at 300 rpm, incubated 10 s, and read Renilla
luminescence. Each miR mimic/reporter construct combination
was performed in triplicate per assay, and at least three independent assays were performed.
Data analyses were performed according to Promega manufacturer instructions. In brief, the Firefly luminescence values
(RLU) measured in each well was normalized for transfection
efficiency to the Firefly luminescence in psiCHECK2 EV control transfected wells for each plate. Then Renilla luminescence
(RLU) was corrected for transfection efficiency (Renilla RLU/
normalized Firefly RLU) within each well. The replicates for each
psiCHECK2 construct cotransfected with nontargeting (NT) control mimics were averaged and used to calculate the fold change
in miR-196b-5p transfected wells for each corresponding psiJournal of Experimental Medicine
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CHECK2 target reporter construct. Data shown are an average or
three independent assays.
Pulldown target site comparison with
argonaute CLIP databases
To further validate the Bi-miR-196b pulldown target binding
sites, all human cell line CLIP datasets for AGO1-4 CLIP-seq
studies were downloaded from CLIPdb (Yang et al., 2015) as
PARalayzer processed .bed files (Table S1). Each dataset was individually uploaded as a unique track in USCS genome browser
(Kent, 2002; Kent et al., 2002; Raney et al., 2014) mapped to
GRCh37/hg19. Since the binding site of the miRNA of interest
must be known for AGO-CLIP data interrogation, we manually
searched for each miR1-96b binding site from a filtered selection
of pulldown targets. All miR-196a-5p and miR-196b-5p miRNA–
mRNA interactions were downloaded from starBase v2.0 (Yang
et al., 2011) using human assembly hg19, with medium stringency of two or more supporting experiments. This resulted
in 874 miR-196 target genes. starBase predictions were overlapped with THP1 pulldown, HEK293 pulldown, and finally the
116 shRNA screen candidates using Venny 2.0 (Oliveros, 2015).
Based on the mature miR-196-5p seed nucleotide sequence target
sites were manually searched and identified using BLAT feature
in the Genome Browser, the corresponding genomic coordinates
are indicated in Fig. S1 (C and D). All target-binding sites were
counted within 22 nucleotides in either direction of the exact
target site coordinates.
MOI determination
To determine the amount of lentivirus required to transduce
murine MLL-AF9 leukemic splenocytes with an MOI of ∼0.2, an
indirect surrogate measurement of transduction efficiency was
experimentally determined. Titration of a random barcoded
lentivirus pool of similar 107 transducing units/ml titer not
containing any hairpins was used. MLL-AF9 leukemic splenocytes were thawed from liquid nitrogen and allowed to recover
for 48 h in standard growth medium RPMI 1640 (Gibco) supplemented with 20% FBS (Hyclone), 60 ng/ml stem cell factor
(SCF), 20 ng/ml IL6, and 20 ng/ml IL3 (Miltenyi Biotech). 106
MLL-AF9 leukemia cells in 100 µl RPMI 1640 supplemented with
20% FBS were mixed with 0, 25, 50, 100, 200, 300, or 400 µl lentiviral supernatant plus 60 ng/ml SCF, 20 ng/ml IL6, 20 ng/ml
IL3, and 10 µg/ml polybrene. Cells were incubated with virus for
6 h at 37°C with 5% CO2. After 6 h, the virus was removed from
cells and replaced with standard growth medium. Cells were
allowed to rest of 48 h in standard growth medium, at which
point they were divided into two replicate wells, one receiving 1
µg/ml puromycin and the other treated with vehicle. After 48 h,
cells were mixed with trypan blue and the number of live cells
in each well was enumerated. Transduction efficiency was calculated using the equation: (no. infected + puro / no. infected
− puro) – (no. uninfected + puro / no. uninfected − puro) =
transduction efficiency. Based on prior studies at the Broad Institute, a transduction efficiency between 30–50% yields ∼80%
of cells getting a single shRNA/cell. We selected the amount of
virus/106 MLL-AF9 cells that achieved 35% transduction efficiency for our shRNA screen.
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MLL-AF9 leukemia engraftment assay, pool size, and animal
number determination
To determine the size of each shRNA pool to obtain sufficient
representation of each shRNA hairpin from the resultant leukemias in the in vivo RNAi screen, murine MLL-AF9 leukemic
splenocytes were prestimulated in growth medium containing RPMI 1640 supplemented with 20% FBS (Hyclone), 60 ng/
ml mouse SCF, 20 ng/ml mouse IL6, and 20 ng/ml mouse IL3
(Miltenyi Biotech). 15 × 106 MLL-AF9 cells were transduced in
growth medium plus 10 µg/ml polybrene with a lentiviral pool
containing over 199,000 unique barcodes (Broad Institute of
MIT Harvard) at an MOI of ∼0.1–0.2. After transduction, cells
were washed then incubated in growth medium for 48 h before
puromycin selection. Transduced cells and 106 untransduced
control cells were treated with 1 µg/ml puromycin for 48 h.
Three sublethally irradiated mice (500 Rad) were each transplanted with 106 puromycin-selected MLL-AF9 cells. In addition,
106 puromycin selected transduced cells were frozen at −80°C
in PBS as pretransplant control. Moribund mice were sacrificed, spleens were harvested, and single-cell suspensions were
treated with ACK to lyse RBCs. Genomic DNA was prepared from
purified MLL-AF9 leukemic cells and pretransplant control cells
using the QIAamp DNA Blood kit (Qiagen). The Broad Institute
performed DNA sequencing and read alignment. Unique barcode aligned reads for each mouse tumor sample were summed
and compared with the aligned reads for each barcode in the
pretransplant control. Random barcoded lentiviruses exert no
selective pressure on MLL-AF9 cells in vivo as they do not specifically target any murine coding sequences. By comparison of
the number of barcodes in the pretransplant hold-back control,
we calculated an engraftment of ∼4% of bulk MLL-AF9 leukemic splenocytes and thus we estimated that shRNA should be
divided into random pools of ∼100 hairpins each, with each pool
containing all control gene (EV, Luciferase, RFP, GFP, and LacZ)
targeting hairpins, and 10 mice/pool to give sufficient representation of each hairpin in vivo.
Selection of gene-targeting hairpins for RNAi screen
Candidate miR-196b pulldown targets were identified from three
independent experiments performed in THP1 AML cells (Table
S1). Targets also identified in HEK293 pulldown and/or in the
cumulative predicted miR-196b target list from four computational prediction algorithms PITA (Kertesz et al., 2007), miRanda
(Enright et al., 2003; John et al., 2004; Betel et al., 2008), TargetScan7.0 (Lewis et al., 2003, 2005; Agarwal et al., 2015), and
DIANA (Maragkakis et al., 2009a,b; Papadopoulos et al., 2009)
were determined (Table S1). Targets were also examined by gene
ontology analyses using the ToppGene Suite (Chen et al., 2007,
2009a,b). Genes with cancer-related biological pathway and
biological processes gene ontologies, and previously validated
miR-196b target binding sites were given priority. The final candidate targets included in the screen were enriched in at least one
THP1 pulldown experiment (n = 116; 38/116 were enriched in ≥2/3
THP1 pulldown experiments represented in Fig. 1 B) and either
(1) present in HEK293 pulldown experiments (n = 60), (2) predicted by computational algorithms (n = 103), or (3) in HEK293
pulldowns and predicted (n = 48; Table S1).
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RNAi screen transduction
MLL-AF9 leukemic splenocytes were thawed from liquid nitrogen and allowed to recover for 48 h in standard growth medium RPMI 1640 (ThermoFisher Scientific) containing 20% FBS
(HyClone) supplemented with mouse recombinant SCF (60 ng/
ml), IL6 (20 ng/ml), and IL3 (20 ng/ml; Miltenyi Biotech). 106
MLL-AF9 leukemia cells in 400 µl standard growth medium containing FBS were mixed with 100 µl lentiviral supernatant. Cytokines (60 ng/ml SCF, 20 ng/ml IL6 and IL3) and polybrene (10 µg/
ml, Sigma) were added to the final volume. Cells were incubated
with virus for 6 h at 37°C with 5% CO2, then virus supernatant
was replaced with standard growth medium containing FBS and
cytokines. Cells were incubated for 48 h, then for an additional
48 h with 1 µg/ml puromycin in fresh growth medium. 106 puromycin-selected cells were transplanted into 10 each sublethally
irradiated (500 Rads) recipient mice, and 5 × 106 cells were held
back in 100 µl PBS at −80°C as pretransplant input control. The
transduction transplantation procedure was repeated for each of
the eight shRNA lentivirus pools. Mice were monitored for illness
and were sacrificed in accord with Institutional Animal Cancer
and Use Committee–approved procedures. Leukemic splenocytes
were harvested and DNA isolated as described.
RNAi screening and data analyses
Leukemic splenocytes were harvested from moribund mice
transplanted with MLL-AF9 cells transduced with shRNA pools,
and single-cell suspensions were treated with ACK to lyse RBCs.
5 × 106 cells/mouse were frozen in PBS at −80°C and 2 × 106 cells
were examined by FACS analysis for expression of known cell
surface markers on MLL-AF9 AML cells CD117, CD11b, and Gr1
expression. The remaining cells were frozen in liquid nitrogen.
Genomic DNA was harvested from all mouse tumor and holdback pretransplant input control samples using the QIAamp
DNA Blood kit (Qiagen). DNA sequencing and read counts were
aligned to the unique barcodes for each individual hairpin shRNA
were performed at the Broad Institute of MIT and Harvard.
To calculate the final representation score for each hairpin,
the following data analysis pipeline was used. Read counts (in
counts per million) for each hairpin were normalized to the sum
of all counts per sample then log2 transformed. Any mouse leukemic splenocyte sample with a sum <10,000 counts per million
was excluded from further analyses. Note that no control samples were excluded. The average log2 normalized value for control hairpins GFP, RFP, and Luc was calculated for each sample.
Individual experimental hairpins were then normalized to the
control average for each sample, and finally the fold change enrichment or depletion scores of each hairpin in the tumor samples were expressed as relative to pretransplant input control
sample. Enriched shRNA was scored with a fold change >0 in at
least 4/10 mice and depleted with a fold change less than −8 in at
least 4/10 mice. To account for potential off-target effects, final
shRNA representation lists included only genes with at least two
hairpins achieving the same directionality in fold change. Genes
with hairpins scoring on both enrichment and depletion lists
were considered “no change” and removed from final representations. To confirm that our scoring method and selection criteria
were not randomly selecting for enriched or depleted hairpins
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but that these represent reproducible shRNA activity in vivo,
replicate mice for each hairpin were divided into two groups per
pool and plotted against each other. The relatedness between
these two groups of mice was compared by Pearson correlation
analysis using Prism 6.0.
RNAi screen gene ontology and network analyses
Gene ontology analyses were performed on the datasets: (1) 116
genes shRNA screen Input shRNA, (2) 33 genes shRNA screen Enriched, and (3) 45 genes shRNA screen Depleted. GO-Elite analyses were performed on all three datasets as Input in AltAnalyze
with a z-score cut-off of 1.96, requirement of at least five changed
genes per category, and the remaining default parameters. Network analyses were performed using AltAnalyze's NetPerspective. The Cytoscape Sets plugin was used to layout the network
according to Gene Ontology terms assigned by GO-Elite (labels
and colored circles added manually).
Lentivirus production, transduction, and gene overexpression
For gene overexpression lentivirus constructs, the pLVX-EIF1αIRES-ZsGreen (Clonetech) vector was digested with EcoRI. The
coding sequence (CDS) for Cdkn1b (NM_009875.4) was downloaded from National Center for Biotechnology Infromation.
Mouse Cdkn1b coding region does not contain any miR-196b
target sites, thus was used directly for overexpression. cDNA
sequences of Cdkn1b were ordered as gblocks from IDT with 5′
(5′-GATCTATTTCCGGTGAATTC-3′) and 3′ (5′-AGAATTCCTCGA
GACTAGTTC-3′) ends homologous to the 5′ and 3′ ends of the
EcoRI site in pLVX. The Kozak sequence 5′-GCCACC-3′ was also
added just before the ATG start site. Gibson Assembly (New England Biolabs) was used to recombine the Cdkn1b gblock with the
pLVX-ZsGreen vector.
Cdkn1b CDS: 5′-ATGTCAAACGTGAGAGTGTCTAACGGGAGC
CCGAGCCTGGAGCGGATGGACGCCAGACAAGCGGAGCACCCC
AAGCCTTCCGCCTGCAGAAATCTCT TCGGCCCGGTCAATCAT
GAAGAACTAACCCGGGACTTGGAGAAGCACTGCCGGGATATG
GAAGAAGCGAGTCAGCGCAAGTGGAATTTCGACTTTCAGAAT
CATAAGCCCCTGGAGGGCAGATACGAGTGGCAGGAGGTGGAG
AGGGGCAGCT TGCCCGAGT TCTACTACAGGCCCCCGCGCCCC
CCCAAGAGCGCCTGCAAGGTGCTGGCGCAGGAGAGCCAGGAT
GTCAGCGGGAGCCGCCAGGCGGTGCCTTTAATTGGGTCTCAG
GCAAACTCTGAGGACCGGCATTTGGTGGACCAAATGCCTGAC
TCGTCAGACAATCCGGCTGGGTTAGCGGAGCAGTGTCCAGGG
ATGAGGAAGCGACCTGCTGCAGAAGATTCTTCTTCGCAAAAC
AAAAGGGCCAACAGAACAGAAGAAAATGTTTCAGACGGTTCC
CCGAACGCTGGCACTGTGGAGCAGACGCCCAAGAAGCCCGGC
CTTCGACGCCAGACGTAA-3′.
The Cdkn1b/p27 Ser10 to Ala mutant (S10A) and p27 cyclin/
CDK-binding mutant Arg30 to Ala, Leu32 to Ala, Phe62 to Ala and
Phe64 to Ala (CK−) were described previously (Vlach et al., 1997;
Besson et al., 2006). The point mutations were introduced into
the murine Cdkn1b CDS (NM_009875.4). The final sequences
were codon optimized for murine expression using publically
available software from Integrated DNA Technologies. Sequences
were ordered as gblocks from IDT with 5′ (5′-GATCTATTTCCG
GTGAATTC-3′) and 3′ (5′-AGAATTCCTCGAGACTAGTTC-3′) ends
homologous to the 5′ and 3′ ends of the EcoRI site in pLVX. The
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Kozak sequence 5′-GCCACC-3′ was also added just before the ATG
start site. Gibson Assembly (New England Biolabs) was used to
recombine the Cdkn1b gblock with the pLVX-ZsGreen vector.
Cdkn1b S10A CDS: 5′-ATGTCAAACGTCAGGGTATCTAATGGA
GCACCTAGTTTGGAACGCATGGACGCTCGGCAAGCCGAGCAC
CCCAAACCCTCTGCCTGTCGGAACT TGT TCGGCCCTGTTAAT
CACGAGGAGCTCACCAGGGACCTGGAGAAGCACTGCAGAGAC
ATGGAGGAGGCAAGCCAGCGAAAATGGAATTTCGACTTTCAG
AACCACAAACCACTGGAGGGCAGGTACGAGTGGCAGGAGGTG
GAGAGGGGGTCTCTGCCAGAAT TTTATTACCGGCCCCCTCGC
CCACCTAAAAGCGCTTGTAAGGTACTGGCCCAAGAAAGCCAA
GACGTAAGTGGCAGCAGACAGGCTGTTCCCCTCATCGGGTCA
CAAGCCAACTCTGAGGACAGGCACCTTGTCGACCAGATGCCC
GATTCCAGCGATAATCCTGCAGGACTCGCCGAGCAGTGTCCT
GGGATGCGAAAAAGGCCAGCCGCTGAAGACTCTAGCTCTCAG
AACAAGAGAGCCAACCGCACTGAAGAGAACGTGTCTGACGGC
AGTCCCAATGCCGGGACAGTCGAGCAGACACCGAAAAAGCCT
GGACTCCGACGGCAGACGTAA-3′.
Cdkn1b CK− CDS: 5′-ATGAGTAATGTTAGGGTGTCTAACGGG
TCTCCTTCTCTGGAGAGAATGGACGCTCGGCAGGCCGAGCAT
CCGAAGCCATCCGCCTGCGCCAATGCCT TCGGTCCTGTGAAT
CACGAGGAGCTCACAAGAGATCTGGAGAAACATTGCCGGGAC
ATGGAGGAGGCCTCTCAAAGAAAATGGAACGCCGATGCCCAG
AACCACAAGCCTCTTGAGGGTCGGTATGAATGGCAGGAAGTC
GAGAGGGGATCTCTCCCCGAGTTCTATTATCGGCCTCCTCGCCCA
CCAAAGTCTGCATGCAAAGTGCTGGCCCAGGAGTCCCAGGAT
GTGAGTGGAAGTAGGCAGGCCGTCCCTCTGATAGGTTCTCAG
GCTAACTCAGAAGACAGGCACCTTGTTGATCAAATGCCTGAC
TCTAGCGACAACCCAGCCGGGCTGGCAGAACAGTGTCCGGGG
ATGCGCAAGAGGCCAGCCGCCGAGGACTATCATCTCAGAACA
AACGCGCTAATAGAACTGAGGAGAATGTTAGCGACGGGTCTC
CTAACGCAGGCACAGTGGAGCAGACCCCCAAAAAGCCGGGAC
TGCGACGCCAGACCTAA-3′.
For lentivirus production, lentiviral vectors Cdkn1b-ZsGreen
(WT p27), S10A, CK− or EV control were cotransfected with lentiviral packaging plasmid Δ8.9 (Naldini et al., 1996) and envelope
plasmid VsVg (Burns et al., 1993) using TransIT-LT1 (Mirus Bio)
into Lenti-X 293T cells (Clonetech). Lenti-X 293T (Clonetech)
cells were cultured in DMEM containing 10% heat-inactivated
FBS (Atlanta Biologics), Pen-Strep (Gibco), and l-Glutamine
(Gibco). Virus-containing supernatant was collected 48 and
72 h post-transfection, and either used immediately or frozen at
−80°C in aliquots.
MLL-AF9 leukemic splenocytes were transduced as described
for the RNAi screen, but with a second transduction repeated
the following day. Cells were allowed to rest of 48 h in standard
growth medium then sorted for ZsGreen+ expression using MoFloXDP (BD Biosciences) at the CCHMC flow cytometry core.
104 sorted cells were divided evenly into methylcellulose M3434
(Stem Cell Technologies) colony forming assays in triplicate, or
5 × 104 cells were transplanted into sublethally irradiated recipient mice (n = 6 per group). For p27 mutant experiments, RNA
and cytospins were also performed using ZsGreen+ sorted cells
48 h post-transduction, and 103 cells were plated in methylcellulose M3434 (Stem Cell Technologies) colony forming assays in
triplicate. Human AML cell lines were transduced with EV, WT
p27, S10A, and CK− lentivirus expressing the ZsGreen fluorescent
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marker. AML cell lines were transduced as described for the RNAi
screen in one round of transduction and allowed to rest for 48 h.
Beginning at 48 h post-transduction, and every 24 h thereafter
for a total of 5 d, an aliquot of each group of AML cells were
examined for ZsGreen+ expression by flow cytometric analyses
using an LSR flow cytometer (BD Biosciences). The percentage of
ZsGreen-expressing cells overtime was measured for each group
and expressed as the frequency of ZsGreen+ cells relative to the
initial time point at 48 h.
Flow cytometric analyses and cell sorting
For the GMP myeloid differentiation analyses, 5 × 106 MLL-AF9
leukemia cells were incubated for 1 h at room temperature
in 50 µl FACS buffer (1% FBS (HyClone), 0.1% NaAzide, PBS)
with a biotinylated lineage antibody cocktail 0.5 µl/antibody
CD3 (clone 145-2C11, BioLegend), CD4 (clone RM4-5, eBiosciences), CD8 (clone 53- 6.7, BD Biosciences), CD19 (clone 6D5,
BioLegend), CD45R (clone RA3-6B2, BioLegend), CD127 (clone
B12-1, BD Biosciences), and Ter119 (clone Ter-119, BioLegend)
plus 0.5 µl of CD16/32-PerCP-eF710 (clone 93, eBiosciences),
CD11b-BV605 (clone M1/70, BD Biosciences), Gr1-PE-Cy5
(clone RB6-8C5, eBiosciences), CD117-BV650 (clone RAM34,
BD Biosciences), Sca1-PE-Cy7 (clone D7, BD Biosciences), and
1.0 µl CD34-BV421 (clone RAM34, BD Biosciences). Cells were
washed with FACS buffer then resuspended in 50 µl FACS buffer plus 0.5 µl Streptavidin-APC-Cy7 (BD Biosciences) and incubated at 4°C until just before analyzing, cells were washed
once with FACS buffer, then analyzed on Fortessa 2 flow cytometer (BD Biosciences). For bone marrow chimerism, 106 ACK
treated bone marrow cells were stained in 100 µl FACS buffer
with 1 µl FcγRIII/FcγRII block (clone 2.4G2, BD Biosciences),
1 µl CD45.1-BV605 (clone A20, BioLegend), and 1 µl CD45.2FITC (Clone 104, BioLegend) for 1 h at RT. Cells were washed
and resuspended in FACS buffer plus PI and analyzed on the
Fortessa 2 flow cytometer. For all analyses, cells were gated on
the live populations with doublets excluded. Cells analyzed on
Fortessa 2 flow cytometer (BD Biosciences). All biotin-lineage
(Lin) positive cells were excluded leaving Cd11b+Gr1+Lin− cells
from which the c-Kit+ population was further defined as GMP
by CD34+ and CD16/32+. Leukemic GMP cells were divided for
CD11bhi and CD11blo or Gr1hi and Gr1lo expression by setting the
gates for all samples based on the median CD11b or Gr1 expression in WT MLL-AF9 control cells. For all analyses cells were
gated on the live populations with doublets excluded.
For isolation of c-Kit+ MLL-AF9 leukemic splenocytes fresh
or frozen leukemia cells were incubated with mouse CD117 Microbeads (130-091-224, Miltenyi) according to the manufacturer’s instructions. The c-Kit+ and c-Kit− fractions were sorted on
the AutoMACs Pro (Miltenyi).
Cell cycle analyses
ZsGreen+ EV, WT p27, S10A, or CK− transduced murine MLL-AF9
leukemic splenocytes and human AML cell lines THP1, MV4;11,
and MOLM13 were treated with 1 µl Vybrant DyeCycle violet
stain (ThermoFisher Scientific) at 106 cells in respective growth
medium and incubated for at least 30 min at 37°C at 5% CO2 in
accordance with manufacturer instructions. Cells were anaJournal of Experimental Medicine
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lyzed for violet dye using the violet laser and acquired at <1,000
events/second on the LSR flow cytometer (BD Biosciences) in linear scale. Cell cycle analyses were performed on ZsGreen+ gated
alive single cells using the Cell Cycle platform in FlowJo v10.0.7
(FlowJo, LLC). Cell cycle analyses were confirmed for each p27
construct or EV control in all three cell lines in at least two independent experiments.
RNA-seq analyses
Leukemic splenocytes were harvested from mice transplanted
with MLL-AF9 leukemia transduced with either Cdkn1b shRNA
(n = 2 mice), Phc2 shRNA (n = 3 mice), or NT control shRNA (n
= 2 matched experimental control mice in Cdkn1b-knockdown
study group and n = 3 mice matched experimental controls in
Phc2-knockdown study group). RBCs were lysed with ACK, and
5 × 106 leukemia cells were lysed with Trizol. RNA quality and
quantity were measured by Agilent Bioanalyzer at CCHMC Microarray Core. Then samples with a RNA integrity number >8.0
were processed by poly-A selection, stranded True-seq, pairedend 75 bp 20 million reads by the CCHMC Sequencing Core. The
fastq files were aligned to mouse genome Mm9 using BowTie 2
and TopHat 2 (Trapnell et al., 2009; Kim et al., 2013). Gene level
fragments per kilobase of transcript per million mapped reads
were obtained using Cufflinks 2 (Trapnell et al., 2010) and further processed in AltAnalyze 2.0.8 to identify differentially expressed genes using default parameters moderated t test with
Benjamini-Hochberg multiple testing correction, raw p-value
cut-off of 0.05, and an expression cut-off of twofold.
GSEA analyses
Log2 RNA-seq expression derived from total leukemic splenocytes
from two independent Cdkn1b shRNA (“Cdkn1bsh”) with two independent NT shRNA controls (“NTsh”), and three independent
Phc2 shRNA (“Phc2sh”) with three independent NT shRNA controls (“NTsh”) were imported into GSEA v.2.2.0 (Mootha et al.,
2003; Subramanian et al., 2005). A fold change ranked gene list
was created comparing the Cdkn1bsh or Phc2sh to NTsh control
samples using the Diff_of_Classes ranking metric and genes were
sorted by descending order real mode. GSEA analyses were run
using 1,000 gene_set permutations of gene sets in the website
gene matrix database with the weighted enrichment statistic.
Results are reported for the most highly positively correlated
and negatively correlated hematopoietic-related gene sets with
leading edge analyses.
To dissect the Myc-regulated, from non-Myc regulated genes
within with Wong ESC core gene set (Wong et al., 2008), all of
the Myc ChIP-Chip identified direct target genes in ESC (Kim
et al., 2008) and the Myc core module genes (Kim et al., 2010)
were subtracted from the Wong ESC core gene set. Then GSEA
analysis was performed as described above for enrichment of the
“Myc-regulated ES core” (n = 168 genes) and “non-Myc regulated
ES core” gene sets (n = 124 genes) in Cdkn1bsh MLL-AF9 cells
compared with NTsh control. See Table S2 for gene sets.
Gene ontology analyses
Gene ontology analyses were preformed using ToppFun in the
ToppGene Suite (Chen et al., 2007, 2009a,b).
Meyer et al.
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In vitro colony forming assays
Equal numbers of cells were mixed with methylcellulose M3434
complete with cytokines SCF, IL6, IL3, and EPO (Stem Cell Technologies) according to manufacturer’s instructions in triplicate.
104 cells/plate were seeded in all studies using transduced bone
marrow cells, 103 cells/triplicate were divided evenly/plate for
studies using purified c-Kit+ leukemic splenocytes, and 103 ZsGreen+ leukemic splenocytes were seeded per plate in triplicate
for p27 overexpression studies. On day 7 immortalized/transformed colonies >1,000 cells were enumerated. Colonies were
dissociated with PBS, single cell suspensions were counted, and
either equal numbers of cells were replated or used in other indicated downstream applications. Each group was performed in
triplicate and results were repeated in independent experiments
at least twice.
Limiting dilution transplantation assay
Leukemic splenocytes were isolated from moribund CD45.1
C57BL/6J mice (BoyJ, Jackson Labs) transplanted with MLL-AF9
leukemia cells expressing Cdkn1b-targeting or nontargeting control shRNA. c-Kit+ cells were enriched using the CD117 microbead
kit and AutoMACS Pro (Miltenyi) according to the manufacturer’s specifications and then diluted to 1000, 600, 300, 100, or 30
cells/200 µl in PBS. BoyJ transplant recipients (n = 6 mice per cell
dose) were conditioned with a split dose radiation of 500 cGy and
200 cGy 3 h apart, then cells were injected via tail vein. Recipients were sacrificed when moribund or at 90 d after transplant.
Leukemia stem cell frequency was calculated using ELDA software (Hu and Smyth, 2009).
Immunoblot analyses
Cells were lysed in radioimmunoprecipitation (RIPA) buffer
(50 mM Tris, pH 7.4, 1% TX-100, 0.2% Na deoxycholic acid, and
0.2% SDS, HALT complete tab [Roche]). Proteins were quantified
using the Pierce BCA Protein Assay kit (ThermoFisher Scientific)
and equal amounts of protein were run on 4–12% Bis-Tris gradient gels (Invitrogen) according to manufacturer’s instructions.
Proteins were transferred by semi-dry electrophoresis (BioRad)
onto Immobilon-P PVDF (EMD Millipore). Membranes were
incubated overnight at 4°C with anti-p27 3688 (Cell Signaling
Technologies) or HoxA7 ab70027 (Abcam), washed then incubated with anti-mouse or anti-rabbit HRP conjugated secondary
antibodies (GE Healthcare). Membranes were developed on film
with WesternSure Premium Chemiluminescent Substrate (LICOR). The same Immunoblots were reprobed with β-actin clone
AC-15 (Sigma) as loading control. Biotinylated miRNA target
immunoblots and p27Kip1 immunoblots were repeated on lysates
generated from at least two independent experiments each.
In vitro RNAi therapeutic treatments
Standard commercially available NT LNA 5′-ACGTCTATACGC
CCA-3′ and anti–mmu-miR-196b-5p LNA 5′-CAACAGGAAACT
ACCT-3′ were purchased from Exiqon. Custom design LNAs
(Exiqon) to specifically block miR-196b binding to the validated
target sites in human and mouse Cdkn1b include TSB1 5′-ATA
CACAGGTAGTAC-3′, TSB2 5′-ACACAGGTAGTACAA-3′, and TSB3
5′-ATATACACAGGTAGT-3′. For MLL-AF9 LNA treatments, nonJournal of Experimental Medicine
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targeting control, anti-miR-196b, and custom miR-196b/Cdkn1b
target site blocker LNAs were purchased from Exiqon. MLL-AF9
leukemic splenocytes were plated at 5 × 104 c/ml in 96-well plates
and treated with 500 nM of LNA. Treated cells were incubated
overnight. 0.21 × 104 cells from each group were retreated and
plated in triplicate in methylcellulose M3434 in 24-well format.
Colonies were enumerated after 7 d, and then single cell suspensions were generated and lysed in RIPA buffer for Western analyses. Experiments were repeated three times.

sample banking. Institutional Review Board (IRB) approval for this
study was obtained at CCHMC. This study was performed in accordance with the Declaration of Helsinki. Six different AML patient
samples were used with MLL-rearrangements (see Table S3 for
complete genetic information). 50,000 cells were plated in duplicate in a 96-well plate in IMDM containing 20% heat-inactivated
FBS plus 10 ng/ml of each SCF, IL3, IL6, TPO, and FLT3. 22d was
added at the indicated concentrations and cells were incubated
with drug for 3 d, at which point cell viability was measured by
MTS assay (Promega) according to manufacturer’s instructions.

Skp2 inhibitors, cell death, and drug synergy assays
THP1 cells were cultured in RPMI 1640 (ThermoFisher Scientific) containing 20% heat-inactivated FBS (Atlanta Biologics),
Pen-Strep (ThermoFisher Scientific), and l-Glutamine (ThermoFisher Scientific). Cells were maintained at subconfluency and low passage at 37°C in 5% CO2. MV411 and MOLM13
cells were cultured similarly except in supplemented with
10% heat-inactivated FBS. For cell death analyses, cells were
plated in duplicate at 0.3 × 106 c/ml and treated with 0, 12.5,
25, or 50 µM SLZ P1-41 (Tocris) or equivalent DMSO vehicle
control and incubated for 3 d. Cells were then stained for AnnexinV–Pacific Blue (BioLegend) and propidium iodide (PI; BD
Biosciences) in AnnexinV Binding Buffer (BioLegend) according to manufacturer instructions. Cells were analyzed on LSR
II or Fortessa 2 flow cytometers (BD Biosciences). Results are
graphed as average percentage alive cells as defined by AnnexinV− and PI−. The amount of inhibitor chosen for p27 immunoblots corresponded with the lowest dose of inhibitor to
have a significant effect on cell viability in the 3-d treatment
time course studies. Cells were treated for 24 h with indicated
amounts of inhibitor then lysed in RIPA buffer and frozen at
−80°C followed by immunoblot analyses to detect p27. Experiments were repeated at least twice.
For synergy assays, we synthesized the previously published
Skp2-Cks1 inhibitor N-(5-(pyridin-3-yl)quinolin-8-yl)-3-(trifluoromethyl)benzenesulfonamide, referred to as compound
22d (Singh et al., 2015), resuspended in DMSO. 22d was titrated
on THP1, MOLM13, and MV;411 cell lines with and without
Ml-1 (Sigma), IBET-151 (GSK1210151A, Sigma), or Palbociclib
(PD0332991, Selleckchem). Three doses of ML1, I-BET151, or Palbociclib were determined by dose titration studies by CellTiter
Glo assay, and three concentrations surrounding the relative IC50
concentrations for each drug in each cell line were used for synergy studies (data not shown). AML cell lines were plated in triplicate at 0.106 cells/ml. Cell lines were treated with inhibitors 22d,
IBET-151, Ml-1, or Palbociclib, or vehicle and cultured for 72 h.
CellTiter Glo (Promega) was used according to manufacturer instructions to measure cell viability. The relative cell viabilities
were calculated for each drug or drug combination compared
with vehicle treated control cells. Drug synergy was calculated
using CompuSyn software by ComboSyn, Inc. (Chou, 2006).

Statistical analyses
Except where described for Microarray, RNA-Seq, and RNAi
screening, all statistical analyses were performed using Prism 6
(GraphPad Software). For RT-qPCR differences in gene expression or pulldown, enrichments were evaluated by ratio paired
parametric t test assuming Gaussian distribution. For ESC core
gene expression RT-qPCR, differences were evaluated by twoway ANOVA Holm-Sidak multiple comparisons test. For flow
cytometric analyses differences in populations were compared
by two-way ANOVA Bonferroni’s multiple comparisons test. Differences in average colony numbers (CFU assays) were evaluated
statistically using two-way ANOVA Bonferroni’s multiple comparisons test or one-way ANOVA Holm-Sidak multiple comparisons test as indicated. Differences in target site dual luciferase
reporter assay repressions were evaluated by two-way ANOVA
Sidak’s multiple comparisons test. Differences in Skp2 inhibitor
SLZ P1-41 dosage response were evaluated by multiple unpaired
t tests with Holm-Sidak multiple testing correction.

Primary human AML
De-identified viably frozen purified mononuclear cells from peripheral blood and bone marrow of AML patients were obtained
from patients at CCHMC. Informed consent was obtained before
Meyer et al.
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Data availability
Microarray and RNA-seq data can be accessed in the Gene Expression Omnibus accession no. GSE75843.
Online supplemental material
Supplementary information includes five figures and three tables.
Fig. S1 shows the optimization, characterization, and validation of
biotinylated miR-196b mimic target pulldowns. Derepression of
miR-196b pulldown targets in miR196 knockout mice is shown. Fig.
S2 shows enrichment and depletion scores of shRNA performance
in the in vivo shRNA screen and examples of shRNA-mediated
knockdown of miR-196b pulldown target RNA levels in MLL-AF9
AML. Fig. S3 shows heat map of Phc2 knockdown MLL-AF9 gene
expression and Cdkn1b knockdown effects on MLL-AF9 transcriptional programming and immunophenotype. Fig. S4 shows
p27Kip1 induces cyclin/cdk-dependent cell cycle arrest in MLL-r
AML. Fig. S5 shows p27Kip1 levels in human AML treated with
SCFSkp2 inhibitors. Table S1 contains 10 tabs of biotinylated miR
mimic pulldown microarray enrichment results, accession nos. of
AGO-CLIP data, miR-196 target predictions, details of each hairpin
in the shRNA screen, average enrichment and depletion scores
for shRNA screen hairpins, shRNA screen gene ontologies, and
RNA-seq on E9.5 embryos with limiting miR-196 alleles. Table S2
contains seven tabs of RNA-seq and GSEA results from Cdkn1b and
Phc2 knockdown MLL-AF9 AML. Table S3 contains drug synergy
data, genomic alterations of primary human AML patient samples, and SNP validation of human AML cell lines.
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